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Section A. Introduction  
 
Clinical science and care of diabetes presents a 
major challenge for strategic mapping. The strategy 
must take into account all aspects of research into 
the care of people with diabetes mellitus, and it 
must include a multiprofessional dimension. Within 
DIAMAP the research Goals for clinical science and 
care are extensions of the Goals and priorities of 
other groups in the project and the translation of 
these into improving the lives of people with 
diabetes. The possible ‘menu’ of clinical and clinical 
science topics is huge. The group deliberately 
prioritised a number of areas (and omitted others) 
with the aim of focussing attention on options that 
could truly alter the delivery and quality of care for 
people with diabetes throughout their lives.  The 
fragmentation of care, the inequality of access to 
care throughout Europe as a whole and the 
vulnerability of many special groups, due to 
geography, age or ethnicity, are major themes. 
Hypoglycaemia is prioritised as it remains a major 
fear of patients, a source of morbidity and mortality 
and an obstacle to metabolic control. Another major 
focus is paediatric diabetes, presented in a new 
context of disease staging and the start of the life-
course. All aspects of diabetes in women of 
reproductive age are highlighted, again in the 
context of lifelong care, and the implications for 
both mother and child and the progression of health 
risks in the offspring in later life.  Mental health is 
prioritised as is quality of life with diabetes care.  
Ageing itself is highlighted, with the increasing 
insight that diabetes is itself a disease of early 
ageing.  There is also a focus on treatments for 
severe or morbid obesity, in recognition both of the 
stark implications of the modern obesity pandemic 
for the prevalence of insulin-resistant type 2 
diabetes, and the rapid progress in the field of 
bariatric surgery, where much more research is 
needed to define risks, benefits and costs to 
patients and society. 
 
While the major diabetes trials of the past two 
decades have changed clinical practice, many 
questions remain unanswered and new questions 
have arisen. The epidemiology of diabetes has 
continued to evolve rapidly, with marked increases 
in prevalence especially in Asia, and in ethnic sub-
populations in Europe. A recurring theme is the 
impact of diabetes on vulnerable sub-groups This 
problem is growing as a result of factors such as 
immigration and increased longevity.  
 
Defining treatment targets more directly according 
to the specifics of the patient, including disease 
phase (see also ‘staging’ of disease in children), 
life-phase (age) and the presence or absence of 
complications is a natural extension of the findings 
of the recent tight control studies, such as Action to 
Control Cardiovascular Risk in Diabetes 
(ACCORD), where more aggressive metabolic 
approaches in older, more complex patients led to 
some increase in adverse events. Hypoglycaemia 
remains one of the most important limitations to 
quality of life for people with diabetes and a key 
adverse outcome of treatment, in both type 1 
(where it is much more frequent) and type 2 
diabetes (where it is less frequent, but potentially 
more dangerous in patients with underlying 
complications). Greater understanding and 
development of new technologies including insulin 
pumps and glucose sensors, as well as the 
educational approaches (including the incorporation 
of telehealth) needed to make these treatments 
effective and the cost implications are cornerstones 
for diabetes research. A range of clinical research 
programmes could result from the topics emerging 
from this area of study. 
 
The wide variability in the actual care provided to 
patients with diabetes across the continent of 
Europe is acknowledged within this road map. 
Vulnerable sub-groups exist in all countries and 
regions; however, overall access to education, care 
and specific therapies also depends on geographic 
location. Health records should be addressed, as 
well as variability in the itinerary of care (from 
primary care to specialist and back) in different 
countries and regions. This research approach is 
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novel when applied across Europe but would lead 
to important insights into the unequal and excess 
mortality and morbidity associated with diabetes in 
certain regions and sub-populations. Integrating the 
itinerary of care across Europe would help to 
address the challenge presented by gestational 
diabetes and type 2 diabetes in women, along with 
the devastating consequences in future generations 
of children.  
 
Children with diabetes are a vulnerable group, and 
paediatric diabetes research has struggled to 
advance, partly because of fragmentation of the 
specialty and the small numbers of patients per 
clinic. A new challenge is the appearance and rapid 
increase in type 2 diabetes in obese children and 
adolescents. This is addressed by DIAMAP in 
discussing the paediatric research strategy in terms 
of staging of diabetes in relation to age, duration of 
disease, reserve of beta cell insulin secretion, and 
presence of complications and/or co-morbidities. 
This approach encompasses the accelerated 
prevalence of both type 1 and type 2 diabetes in 
children and adolescents, and provides a platform 
for research in all variants of childhood diabetes. An 
additional priority is the somewhat neglected field of 
transition of care between paediatric care and adult 
diabetes care.  This a key phase during the life of a 
young person with diabetes, where the patient often 
gets ‘lost’ in the gap between two very different 
types of clinical service.  Much more research and 
attention is needed to improve this period of the life 
of young patients. 
 
Conversely, the European population in general is 
ageing, and incidence of diabetes increases rapidly 
with advancing years. This will have an increasingly 
negative impact upon society and the economy if 
not addressed now. Ageing itself is a research 
theme in its own right, and is especially relevant to 
diabetes research, since diabetes often causes 
acceleration of ageing, particularly in vascular 
tissues. 
 
There is potential to markedly reduce costs of care 
and to improve the quality of life for patients in long-
term institutional care if an integrated research 
approach is taken. There is an overwhelming need 
for diabetes registries, for improved information 
systems and for integration and standardisation. 
The resistance to large-scale clinical research in 
the traditional clinical setting hinders any progress 
in the area.  
 
Inexorable decline in beta cell insulin secretion is 
the key parameter leading to progression of all 
forms of diabetes, although the techniques for 
measuring this process in human beings have been 
inadequate and remain at best rather inexact. 
Mathematical modelling has played an important 
role in clinical research in this area over the past 30 
years. Better test algorithms that can be conducted 
at the bedside to calculate islet cell mass and 
function, along with the use of mathematical 
methods to integrate islet-related metrics in the 
context of multiple other variables, such as insulin 
sensitivity, and hepatic and renal function, remain 
important research goals that would support clinical 
science and care in diabetes. 
 
Taken as a whole, the Clinical Science and Care 
sub-group sought not only to draw together these 
diverse research pathways but also examine them 
in the context of the quality of life of the patient, 
along with an analysis of societal and economic 
benefit. Such a strategy could be undertaken on a 
large European scale if a European Platform for 
Clinical Research in Diabetes (EPCRD, see Goal 
4.1) could be created and supported by the 
European research institutions. Many clinical 
research questions can only be answered with a 
broad trans-national approach.  
 
 
 
 
 
 
  
 
 75 
Section B. Scientific advances and major challenges  
 
This is an outline of the main scientific advances 
over the past decades that may serve as platforms 
for research maps for the future. These are 
grouped under six main thematic areas: 
 
Diabetes Care 
• Education: the development of structured 
educational approaches for patients with 
diabetes, such as Dose Adjustment for Normal 
Eating (DAFNE), Diabetes Education and Self-
Management for Ongoing and Newly 
Diagnosed (DESMOND). This is still an area 
under development and includes the field of 
age-appropriate education for vulnerable sub-
groups such as children, pregnant women, and 
patients with disability.  This field is in fact in its 
infancy, and much more research will be 
required to develop educational tools and 
systems that ‘fit’ the lives of real people across 
the huge spectrum of ages, ethnicity, and 
cultural and dietary traditions. 
• Settings of care: the development of integrated 
care systems for people with diabetes, between 
specialists and primary care physicians. 
• Multidisciplinary and multi-target oriented care 
of diabetes, as demonstrated in the Steno 
studies for type 2 diabetes and in the Diabetes 
Control and Complications Trial (DCCT) for 
type 1 diabetes. 
• Quality of Life: newer methods to evaluate the 
effects of diabetes, its complications and its 
treatment on quality of life. Patient-oriented 
outcomes that matter (POEMS). 
• Diabetes registries: developed in various 
regions, with multiple benefits for care, but not 
yet in widespread use nationally or 
internationally. 
 
Diabetes Control and Complications 
• The DCCT and the Epidemiology of Diabetes 
Interventions and Complications Study (EDIC) 
in type 1 diabetes. The original landmark DCCT 
study proved that intensive glycaemic control 
reduced microvascular complications of 
diabetes. The EDIC follow-up of this cohort 
proved the extended benefit of intensive control 
over time to reduce macrovascular 
complications. 
• UK Prospective Diabetes Study (UKPDS) and 
follow-up studies in type 2 diabetes. This 
landmark study proved the benefit of glycaemic 
and blood pressure control in patients with type 
2 diabetes. UKPDS also posed the challenge of 
solving the problem of macrovascular disease 
prevention in type 2 diabetes, which is clearly 
more complicated than glucose control alone. 
• Studies of lipid lowering: the Heart Protection 
Study and the Collaborative Atorvastatin 
Diabetes Study (CARDS), among others, 
provided clear evidence for the substantial 
benefit of statins in low-density lipoprotein 
lowering in type 2 diabetes. Less clear has 
been the question of fibrates and the question 
of triglycerides/HDL manipulation in preventing 
complications. 
• Multi-target tight control studies in type 2 
diabetes, including the cluster of Action to 
Control Cardiovascular Risk in Diabetes 
(ACCORD), Action in Diabetes and Vascular 
Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE), 
and Veterans Affairs Diabetes Trial (VADT) 
studies, all reporting during the same period. 
These studies posed the dilemma of possible 
harm of over-tight glycaemic control 
(particularly with insulin) in older subjects with 
cardiovascular disease. 
• Recent evidence indicates that some 
categories of patients may not benefit from a 
tight glycaemic approach, and may be safer 
when treated to less rigorous glucose targets.  
More research is required to understand how 
these targets should be adjusted to take 
account of age, prior cardiovascular 
complications and other factors that may 
influence this treatment approach. 
• Endpoint studies of new drugs: including A 
Diabetes Outcome Progression Trial (ADOPT), 
Prospective Pioglitazone Clinical Trial in 
Macrovascular Events (PROACTIVE). More 
studies of this type are needed to provide 
knowledge about the medium- to long-term 
effects of new therapies on disease 
progression and disease complications as well 
as quality of life. 
• Longer term studies of insulin therapies: such 
as the recent 4T study, formally comparing 
three insulin regimes over 3 years in type 2 
diabetes. 
• Trials of therapies to treat blood pressure and 
prevent nephropathy: starting with the landmark 
study of angiotensin-converting enzyme  
inhibition by Lewis in 1993, there have been a 
large number of these studies, many including 
sub-groups with diabetes and some specifically 
studying only patients with diabetes. 
 
Diabetes in special sub-populations 
• Pregnancy and gestational diabetes mellitus 
(GDM): including the Hyperglycemia and 
Adverse Pregnancy Outcomes (HAPO) Study, 
the Australian Carbohydrate Intolerance Study 
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in Pregnant Women (ACHOIS) study, the 
Confidential Enquiry into Maternal and Child 
Health (CEMACH) Report, Metformin in 
Gestational Diabetes (MiG) trial and the 
Glyburide Trial. 
• Paediatrics: including European Collaborative 
Paediatric Groups [Better control in Pediatric 
and Adolescent diabetes: working to create 
Centres of Reference (SWEET); Pedpumps, 
Hvidore-Group], studies by the International 
Society for Paediatrics and Adolescent 
Diabetes (ISPAD). 
• Morbidly obese patients: The new and growing 
field of bariatric surgery for the treatment of 
type 2 diabetes. 
 
Diabetes and novel technologies 
• Insulin pump therapy: pumps have evolved 
rapidly since 1980, becoming much smaller and 
with more sophisticated software and 
hardware. 
• Glucose sensors and continuous glucose 
monitoring (CGM) devices: sensors have 
improved but remain a niche area and are not 
widely available to patients. Non-invasive 
sensors are still under development. 
• The connection of CGM with continuous 
subcutaneous insulin infusion (CSII) by a 
mathematical algorithm to form an ‘artificial 
pancreas’ is an ultimate goal of diabetes 
research. Meanwhile, progress towards a 
commercially available closed-loop system has 
moved forward recently in three areas: 
o technologies to ‘shut-off’ the insulin infusion 
as hypoglycaemia develops 
o hybrid systems incorporating pre-meal 
boluses with a closed-loop system to 
reduce daytime glucose variability and  
o a closed-loop system with enhanced 
algorithms to reduce glucose variability and 
the risk of hypoglycaemia overnight. 
• Stem cell technologies and transplantation: islet 
transplantation had been the main hope in this 
field (with the aim of curing type 1 diabetes). 
The Edmonton protocol for islet transplantation 
and immunosuppression showed very 
promising initial results, but long-term clinical 
results beyond 5 years have been 
disappointing. Ultimately, demand for islet 
transplantation far exceeds supply. Two to 
three whole pancreases are required to treat 
one patient, and for example only 6,000 
pancreases are donated annually in the whole 
United States. Stem cell technology holds 
promise for the treatment of type 1 diabetes, 
but many obstacles remain, including questions 
around immunosuppression, regulation of the 
transplanted cells’ secretory functions and the 
danger of cancer. 
• Laboratory standardisation: the standardisation 
of HbA1c (and many other assays such as 
insulin, lipids) and the development of 
alternative metrics of ongoing metabolic 
control, such as average blood glucose, are 
key new developments that will change 
diabetes care in the next decade. 
• The field of mathematical modelling in the 
physiology and pathophysiology of diabetes 
has been pioneered in the last 30 years. This is 
now an established research area with the 
potential to greatly improve the accuracy and 
convenience of phenotyping patients in terms 
of insulin secretion and action, and to support 
the newer technologies including all of those 
listed above. 
 
Whole-body physiology in patients with 
diabetes 
• The development of ‘gold standard’ methods to 
measure insulin action (the hyperinsulinaemic 
clamp technique), insulin secretion (the 
hyperglycaemic clamp and several other 
methods) and other parameters of whole body 
metabolism are landmark advances in the past 
30 years. The challenge now is to translate 
these research approaches to newer, more 
convenient and patient-friendly methods to 
study whole body metabolism in larger 
numbers of patients to support the aim of 
individualising therapy. 
 
Prevention of diabetes 
• Type 2 diabetes has been shown to be 
preventable in several large studies, particularly 
the landmark Finnish Diabetes Prevention 
Study and the National Institutes of Health 
Diabetes Prevention Program (NIH DPP). 
• Many obesity intervention studies (lifestyle and 
drug therapies) by their design constitute 
diabetes prevention studies. 
• Major epidemiological studies, such as 
Diabetes Epidemiology: Collaborative analysis 
of Diagnostic Criteria in Europe (DECODE), 
have delineated and more precisely defined the 
‘prediabetes’ population(s) and have laid the 
foundations for future prevention studies. This 
field has also developed methods for the 
estimation of risk of developing diabetes (for 
example, the FINDRISK score), which may 
ultimately replace blood testing for initial 
screening at a population level. 
• Type 1 diabetes prevention remains elusive; 
while there have been a number of negative 
trials, several newer approaches are under 
study. 
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Section C. Road map reports 
 
Links between Goals and Milestones in the DIAMAP report are noted within the text and also in the diagrams 
in italics. Roadblocks are listed below the diagrams and described at the end of the chapter and shown in 
red circles. Goals and Milestones considered a priority are indicated with a broken green line.  
 
 
Goal 4.1 Create a European Platform for Clinical Research in Diabetes (EPCRD) to 
facilitate and enhance diabetes clinical research for improved care and treatment of 
people with diabetes throughout Europe 
 
 
 
   Roadblock 1. Ethical guidelines: in particular regarding data sharing and transfer, collection and use of biological  
    materials including DNA 
   Roadblock 2. Variation, lack of standardisation or international consensus across Europe in laboratory conditions,  
    measurement techniques, sample handling and clinical diagnoses and practice  
 
 
 
Introduction and background 
Within the European Union there are increasing 
numbers of adults and children with diabetes. 
Despite guidelines and consensus statements 
related to approaches, targets and therapies, 
across Europe there remains huge variation in the 
quantity and quality of diabetes-related clinical 
research and health care available for people with 
diabetes. This variability in research activity and 
service delivery is a consequence of many factors, 
the most significant being the social and cultural 
differences among countries, differences in clinical 
governance, and lack of structured networks of 
interested parties with commonly agreed goals.  
 
Aims and objectives 
The aims of the European Platform for Clinical 
Research in Diabetes (EPCRD) are to: 
• Facilitate and enhance clinical diabetes 
research with the purpose of improving care 
and treatment for people with diabetes.  
• Facilitate access to data and biological samples 
by providing a uniform agreed and ethically 
approved infrastructure to permit sample and 
data sharing across multiple national and 
international security barriers. 
• Improve access to structured education and 
training for European diabetes researchers and 
healthcare professionals engaging in research 
activity, and for people living with diabetes. 
• Create centrally determined governance 
structures in line with current ethical guidelines.  
• Facilitate access to information and online 
databases of clinical studies and trials, thus 
encouraging participation by interested 
volunteers (with diabetes and without). The 
closer dialogue between professionals and 
research participants is intended to encourage 
greater understanding of the science.  
• Streamline the processes for dissemination of 
research findings through a dedicated 
communication channel including a 
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consultation process with people with diabetes 
and the public.  
• Encourage investment by and participation of 
industry, facilitating access to a large number of 
research subjects and to scientists from sub-
specialties. Funding of industry-initiated trials 
could be standardised across Europe 
supporting the concept of the ‘European 
diabetes patient’. The use of such a market 
approach to clinical research has the potential 
to drive down costs to increase the 
competitiveness of Europe as a clinical trial 
location. 
 
Advantages of an EPCRD 
A large population of people with diabetes with 
variations in genetic and ethnic background (and 
family members) could be made accessible to 
clinical (and basic) researchers and the sponsors of 
research by participation in a network with a 
centralised point of entry. The DIAMAP road maps 
have repeatedly mentioned as roadblocks the need 
for registries of people with diabetes, networks of 
specialist researchers, access to biobanks and 
human biological material (especially in relation to 
the rarer complications) and the need for more 
standardised evidence-based treatment guidelines. 
The majority of roadblocks are addressed within the 
Horizontal Issues report by engaging with 
organisations or individuals external to the research 
community. However, it was felt strongly that 
diabetes research would be enhanced if the clinical 
research community itself could drive a 
collaborative initiative as it deals with the 
consequences of research upon treatment and care 
delivery (this Goal is linked with many Goals and 
Milestones throughout the road maps). 
 
European clinical research has limitations 
compared with the United States in that access to 
large numbers of people with diabetes and healthy 
volunteers with specific characteristics in single 
centres is difficult. Clinical research, from small 
studies to large-scale pharmaceutical trials, or 
research into health service provision is more 
laborious and less representative than it could be 
because of the number of countries, languages and 
organisational cultures. The EPCRD would facilitate 
research in such situations.  
 
Limitations of an EPCRD 
The roadblocks list the limitations of an EPCRD, 
mainly concerning privacy of data and difficulties of 
data and sample transfer across borders. Also, 
participation is likely to vary in different countries, 
which may cause a cultural imbalance. The 
establishment of an EPCRD should ideally be 
piloted in a small number of locations, with 
operations directed from a central office, before any 
wider scale network could be envisaged. 
 
Characteristics and essential functions of an 
EPCRD 
There are many existing networks and study groups 
that are investigator-led, focussed upon specific 
research areas and funded by individual 
membership, research grants or the pharmaceutical 
industry. Such networks have developed a way of 
exchanging, learning and sharing of research ideas 
and best practices across Europe. Often these 
networks disperse when the grant comes to an end. 
This proposal is to access these networks and 
experience and to develop a more extensive and 
all-encompassing network with a central point of 
organisation. 
 
The concept of a European Platform for Clinical 
Research in Diabetes (EPCRD) is based on the 
understanding that people living with diabetes and 
their families will find it relatively easy to understand 
its value to improve diabetes care. The support of 
the European population is essential and offers a 
significant opportunity for transparency in 
determining how diabetes research budgets are 
spent. The key to the success of the EPCRD is the 
role and consent of the individual person with 
diabetes. Modern technology has revolutionised the 
access to all sources of information for individuals, 
across all traditional borders of language and to 
some extent culture and education. Individual 
patients and their representative organisations will 
provide the impetus and drive to develop the 
EPCRD, once the network is initiated. 
 
The following are necessary for the EPCRD to 
operate, and would need to be established before 
and during the EPCRD road map development. 
• A central physical secretariat from which the 
administration, finance and communications 
could be directed with a central office staff. 
• A legal basis would need to be established to 
facilitate operations; however, to contain initial 
costs the secretariat could be shared with 
another diabetes organisation. It is envisaged 
that much of the work could be carried out in a 
‘virtual’ environment by staff situated remote 
from the physical secretariat. 
• A management structure comprising a 
Scientific Board with decision-making strategy 
for research (as opposed to administrative) 
issues would provide guidance for ethics, 
consent, security and other governance issues 
concerning data and biological material 
collection and storage, location and use of 
biobanks (when established), professional 
training and education, and structure to 
manage telehealth initiatives 
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• The Scientific Board would direct proposals for 
research funding. 
• Other diabetes organisations that have created 
networks would be engaged in dialogue such 
as JDRFI, to exchange expertise and 
appreciation of potential roadblocks. 
• Criteria for involvement of the research and 
health care professionals, research locations 
such as hospitals and general practices, along 
with voluntary entry by patients and research 
volunteers would be decided by the Scientific 
Board. 
 
Milestone 4.1.01. Establish a stakeholder group 
to drive the concept of an EPCRD 
The EPCRD could not function without core 
stakeholder involvement and investment of time, 
expertise and funding. A core group is necessary 
for initial contacts and leading the discussions to 
initiate the enterprise. Engagement from the 
beginning would be with patient organisations [for 
example through the International Diabetes 
Federation (IDF-Europe)] as participation will be 
voluntary and such organisations have good 
connections across Europe.  
 
Representatives from the diabetes scientific and 
clinical communities, patient groups, 
pharmaceutical and biotechnology industries, and 
also individuals with a background in the media 
would be approached as the success of research 
initiatives is dependent upon dissemination and 
translation of the findings into the relevant clinical 
areas. National based groups would be created 
eventually to liaise with the central office. 
 
Milestone 4.1.02. Develop minimum entry 
criteria  
Entry criteria would be determined for individual 
researchers, hospitals or general practices to 
become a part of the collaboration and to publicise 
the network, collect and record the data of patients 
willing to participate. 
 
Governance structures would be developed to 
cover all aspects of clinical trials from developing 
the hypotheses, creating the protocols, developing 
standardised operating procedures, securing 
funding and ethics approval, the running of studies 
and dissemination of the findings. 
 
Milestone 4.1.03. Develop and test appropriate 
information technologies in collaboration with 
patients, clinicians and industry 
The EPCRD is based on the concept that much of 
the data would be handled by a ‘virtual’ research 
unit that would require collaboration between 
researchers and clinicians, people living with 
diabetes, and industry. It is likely that there would 
be a role for qualitative researchers in enhancing 
this aspect of the project.  
 
As it is envisaged to connect experts in particular 
fields in many different locations, this would provide 
the ideal opportunity to develop audiovisual media 
(telehealth) in teaching, especially of research 
techniques, consultation and sharing of best 
practice. 
 
An additional potential benefit of this approach 
would be a database that would allow a much 
greater understanding of the impact of (for 
example) introducing new therapies into the 
diabetes community. It may be possible for people 
with diabetes to report back the impact (or 
otherwise) of a new therapy on surrogate (e.g. 
HbA1c), personal (i.e. socio-economic), or clinical 
(rates of complications) outcomes. This information 
would be invaluable for health economic and health 
commissioning considerations. 
 
Regular dialogue could be established between the 
EPCRD and the bodies governing testing and 
licensing of medicines within Europe such as the 
European Medicines Agency and other bodies such 
as the European Forum for Good Clinical Practice. 
 
Milestone 4.1.04. Identify resources to support 
the EPCRD infrastructure 
There are already tested and functioning models of 
academic and industry (also looking beyond the 
pharmaceutical industry) partnerships to support 
research as well as patient organisations. Such 
partnerships could be fostered within the EPCRD to 
support research and to develop new ideas.  If a 
synergy between academia and industry could be 
created this would resolve many of the roadblocks 
identified within the DIAMAP road maps. 
Developing new funding streams and methods of 
financial support is important, in part because 
funding is finite and is already stretched between 
competing organisations and projects.  
 
Milestone 4.1.05. Identify regional, national and 
cultural incentives to encourage participation in 
the EPCRD 
There appears to be significant variation in the 
delivery of diabetes care across Europe. The 
EPCRD would allow for comparisons to be made 
between different methods of healthcare delivery 
using quantitative and qualitative methods, which 
would allow for national considerations.  
 
Developing a network of people with diabetes 
would be extremely attractive to those countries 
that do not have access to registries, and would 
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offer those countries that do have registries the 
possibility to augment the data and to access, for 
example, information on rare conditions.  
 
Milestone 4.1.06. Compare the EPCRD to 
traditional research approaches  
The EPCRD should be continuously evaluated to 
ensure that it remains true to its original aims and 
that it compares well with more traditional methods 
of locating research subjects and managing 
research administration. It must be emphasised that 
it is not proposed that the EPCRD should take over 
research that would otherwise be carried out at the 
national level. It must provide added value with 
evidence that the approach is cost-effective, that 
people with diabetes support the EPCRD and that 
positive aspects of national delivery of diabetes 
healthcare are enhanced. 
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Goal 4.2. Achieve comparable outcomes for people with diabetes regardless of 
socio-economic status and diversity 
 
 
   Roadblock 3. Practical and ethical challenges of locating research participants among diverse groups 
 
 
 
Introduction and background 
There are now many European studies indicating 
links between prevalence of diabetes and socio-
economic status, with lower income groups being 
disproportionately affected by type 2 diabetes. 
These lower income groups are also likely to have 
high immigration populations e.g. the Marolles area 
of Brussels. They are also likely to have a higher 
incidence of obesity (of which type 2 diabetes is a 
consequence). Deprived populations such as these 
are also less likely to be well educated, less likely to 
take up the health services available, and appear to 
be less likely to even locate those services. Many 
deprived populations may also be older adults with 
restricted incomes, mobility and social standing. It 
has been noted with regards to diabetes 
management that such populations are less likely to 
have accurate medical records documenting 
HbA1c, cholesterol and smoking status although 
the reasons for this disparity with higher income 
groups are not clear.  Deprived populations also 
tend to have more micro- and macrovascular 
disease – especially retinopathy and cardiovascular 
disease – and many present with higher HbA1c 
levels than national averages.  
 
Many European countries are experiencing 
economic and budgetary constraints with higher 
unemployment in the face of an economic burden 
of care for diabetes and its complications that is 
likely to rise substantially. This has been 
recognised recently by the World Health 
Organization (WHO) that has indicated the growing 
negative impact of chronic diseases, such as 
diabetes, in terms of national social and economic 
wealth. 
 
The importance of addressing such problems early, 
before expensive complications drain health 
services and affect European productivity, is 
crucial. It is also noted that research approaches 
likely to succeed in tackling these issues are those 
that involve all major agencies and, most 
importantly the targeted populations, through a 
focussed public and patient involvement strategy 
(see also Milestones 1.3.11, 1.5.04, 4.7.02, 4.7.03, 
6.4.01 and Goal 4.3). 
 
Milestone 4.2.01. Understand why type 2 
diabetes is more prevalent in those of low 
socio-economic status 
The higher incidence of diabetes in deprived 
populations is likely to be multifactorial including: 
age; belonging to an immigrant or ethnic sub-group; 
being in a lower socio-economic group; being 
obese; having limited education. If comparable 
incidence and prevalence of diabetes among all 
social groups is to be achieved these sub-groups 
should be the target for specific research.  
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Milestone 4.2.02. Determine diabetes ‘hotspots’ 
in Europe 
In the first instance, areas in Europe where 
incidence of diabetes is higher than the European 
average should be determined so that research can 
be targeted to areas of most need. This can be 
achieved by developing an international diabetes 
registry situated at the point of health service 
provision that can capture demographic 
information, such as socio-economic status, 
ethnicity and age and which could feed into a 
European research database. Such a database 
would require very detailed consent, encryption and 
security features and could best be managed by the 
EPCRD (see also Goal 4.1). 
 
Track 1. User and community involvement in 
research  
 
Milestone 4.2.03. Determine reasons for less 
accurate medical records in deprived areas 
Comparative research is required to determine 
why medical records in socially deprived areas are 
not as complete as those in more affluent regions. 
Qualitative data should be collected from people 
with diabetes on their health services experience. It 
would be important to follow the ‘diabetes treatment 
pathway and patient journey’ for the medical 
records and personal histories of patients so that 
disparities can be viewed from their perspective. 
Such a qualitative research programme would 
ideally include comparison of regional and 
institutional resources. Deprived populations at 
higher risk of developing type 2 diabetes may 
benefit from screening programmes for the 
condition and other health promotion campaigns 
and preventative strategies.  
 
Milestone 4.2.04 Investigate culturally 
appropriate diabetes awareness and healthy 
eating campaigns 
Cultural approaches: Health awareness 
programmes, especially in terms of weight 
management must be researched first to ensure 
they are culturally appropriate, and engage those at 
risk in how they should be conducted. For example, 
in certain religions, physical exercise can only be 
taken with same-sex attendees. Such research 
strategies need to be multi-agency and engage 
local community leaders and groups if they are to 
be effective. A good example is a programme of 
exercise for overweight women through 
Bangladeshi folk dancing. Research also needs to 
focus on culturally specific training for health 
professionals involved in diabetes management of 
ethnic minority groups. For example, in the past 
health professionals in the UK have denied the 
importance of Ramadan and instructed people with 
diabetes to ignore their religious beliefs and not to 
fast during this period. Recent research has 
indicated that people will put their religion before 
guidance from the physician and the assumption 
that people will fast has initiated a number of 
protocols that advise people how to do so 
effectively with diabetes (see also Milestones 
1.3.04, 4.6.08 and Goal 4.3). 
 
Role of local authorities and planners: A very 
broad research perspective towards improving 
health for such communities should be adopted. 
For example if physical activity is difficult due to 
lack of local facilities then health promotion 
campaigns need to engage more readily with town 
planners and local government to collaborate with 
other stakeholders to provide a safe appropriate 
environment. A research project that proposes to 
increase the use of bicycles for transport and 
pleasure needs local agencies to agree to make 
cycle lanes that are safe and therefore likely to be 
used. Research strategies that aim to improve the 
health of deprived populations, must adopt a 
culturally sensitive, multi-agency inclusive approach 
that should involve people from the local community 
in planning, development and evaluation (see also 
Milestone 1.2.04). 
 
Alternative communication strategies: If 
successful campaign strategies can be identified, 
tested and validated through research they can be 
transferred to other population groups and adapted 
to the specific cultural group as appropriate. One 
example is ethnic minority diabetes story telling – a 
different way of imparting health messages, which 
may be more appropriate than more formal 
European education techniques and are highly 
valued by local inhabitants. School children can 
also be excellent ambassadors in immigrant 
populations for healthy eating and exercise; if such 
research could be conducted in schools, health 
messages are then taken home for the benefit of all 
family members.  
 
Older sub-groups: Older people are also a hard-
to-reach group due to several factors. Many may be 
supported by extended family, but a growing 
number live in isolation, such as when their children 
leave rural areas to work in towns or move to other 
countries within Europe in search of better 
prospects. If older people are from immigrant 
groups they may not speak the national language 
or they may already reside in residential homes. 
The higher incidence of diabetes and complications 
in this group is expensive for health budgets 
especially for in-patient care. Several areas here 
require research intervention, including social 
research to bring older adults to the top of the 
agenda. In the past, studies have labelled older 
adults as a ‘burden’ and discussed the ‘ageing time 
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bomb’; this has had a negative impact on older 
populations who are then less likely to seek the 
healthcare they need. To encourage healthy 
ageing, qualitative enquiry needs to recall the 
usefulness of older people in society and how they 
can successfully manage their diabetes with the 
correct assistance. Knowledge of diabetes in 
residential homes for older adults is known to be 
inadequate especially by transient staff who may 
lack understanding of the risks and danger of 
hypoglycaemia and complications. Promotion of 
residential work with older adults as a valuable 
career pathway also needs to be explored (see also 
Goal 4.3). 
 
Track 2. Training and education of health 
professionals working with hard-to-reach 
groups  
 
Research into staff education and training is 
urgently needed. Education and training has been 
mentioned (track 1) but it is of such paramount 
importance that it has been given an individual 
track with regards to health inequities. 
 
Milestone 4.2.05. Develop educational 
programmes for professionals on health 
inequalities  
To achieve comparable outcomes for all people 
with diabetes regardless of ethnicity, age and socio-
economic status, research must address the 
development of an education process for all health 
professionals that draws attention to current 
inequities and how they should be treated. There is 
a current need to evaluate present health 
professional education and develop training that will 
embrace both a multicultural approach and also a 
life-course approach (see also Milestone 4.4.03). 
Such training and educational packages will need 
to be tested and validated before being endorsed. 
Experiences can be shared particularly when 
considering diverse cultures and languages; the 
use of telehealth tools and techniques within a 
Europe-wide platform would be most useful here. 
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Goal 4.3 Improve outcomes for people with diabetes in hospital or institutional 
settings 
 
 
   Roadblock 2. Variation, lack of standardisation or international consensus across Europe in laboratory conditions,  
    measurement techniques, sample handling and clinical diagnoses and practice 
   Roadblock 4. Lack of birth cohorts and registries with repeated examinations for long-term follow-up studies over  
    the life-course  
   Roadblock 6. Fragmented electronic medical records, even within a single institution 
   Roadblock 8. Gap in professional skills 
   Roadblock 10. Resistance to implementation of large-scale clinical research in the setting of usual care and  
    fragmentation of usual clinical care from the tradition of clinical research  
 
 
Introduction and background 
This road map focusses on patients with diabetes 
who are in hospital or in institutional settings, 
including long-term care for the elderly, psychiatric 
hospitals, prisons and other chronic care facilities 
(see also Goals 4.2, 4.5, 4.9). Taken together, this 
group of patients constitutes a particularly 
vulnerable population, whose outcomes are worse, 
often since diabetes can be lost or ignored because 
of the effects of other co-morbidities or 
complexities. If diabetes is neglected or hidden 
behind another illness, metabolic outcomes are 
likely to be sub-optimal, and costs and 
complications likely to increase. 
 
There are two tracks to this road map: 1. acute care 
of short-term illness and emergency situations; 2. 
chronic institutional care of long-term illness. The 
overall goal of this map is to harness research to 
improve the outcomes for these vulnerable patients, 
including morbidity, mortality, length of stay, costs, 
and quality of life (see also Milestone 4.2.04 and 
Goals 4.2, 4.5, 4.9). 
 
Track 1. Acute care 
 
Milestone 4.3.01. Create a new system for early 
detection and registration to identify all people 
in hospital or institutional care who have 
diabetes 
The first step to support this research, and to 
improve patient care, is to be able to identify those 
patients who have diabetes. Currently, diabetes is 
often missed or ignored in these settings, because 
another illness or procedure takes precedence. 
However, it is long known that patients with 
diabetes have worse outcomes, longer hospital 
stays and have higher costs than other patients, 
matched for other clinical variables. Various 
approaches could be taken to solve this problem. 
Accurate diabetes registries on a regional, national 
or even international basis could solve the problem 
for patients already diagnosed with diabetes. 
However, diabetes is often diagnosed for the first 
time while patients are in hospital or institutional 
care. Thus what is also needed is greater 
awareness among carers together with screening 
and integration of laboratory and electronic record 
systems to trigger the diagnosis of diabetes where 
it is already clearly evident, if looked for. 
  
 
 85 
Milestone 4.3.02. Design emergency triggers 
and algorithms 
The acute hyper- and hypoglycaemic emergencies 
related to diabetes are much more common in 
hospital or care settings. Morbidity and costs are 
high, and there is potential for mortality, particularly 
in elderly patients. These emergencies are much 
better treated by algorithms that are standardised 
across regions, countries and continents and with 
specialist input in consultation.  
 
Milestone 4.3.03. Design and compare 
perioperative diabetes algorithms, coronary 
care algorithms, and intensive care algorithms 
The past decade has seen active debate and 
controversy around the management of diabetes 
(and glycaemic control in particular) in the settings 
of acute major illness, such as post myocardial 
infarction and the intensive care unit. The zeal for 
intensive glycaemic management that initially held 
promise has been followed by more recent 
scepticism and awareness of the potential for harm 
in such approaches. There is a requirement for 
further research across a large number of centres, 
with sufficient statistical power and with 
appropriately matched patient groups in terms of 
other clinical variables. These studies are crucially 
important for the short- and long-term health of 
hospitalised patients with diabetes, both in terms of 
morbidity, mortality and cost of care. 
 
Milestone 4.3.04. Test and validate new 
treatments: acute care 
Up to now, most of the major clinical trials of new 
diabetes treatments have been conducted in 
moderate numbers in an outpatient setting. Results 
from these studies cannot be generalised to the 
very different and more complex population of 
people in hospital with diabetes. Given the high 
prevalence of diabetes in patients in hospital or 
long-term institutional care (track 2), there is an 
opportunity to design a whole range of new trials in 
these populations. Such a strategy raises several 
roadblocks, mostly around the traditional separation 
between clinical research and usual clinical care, 
particularly in hospitals. This approach promises to 
reduce both morbidity and mortality in the 
vulnerable population of those in hospital with 
diabetes (see also Milestone 4.3.07). 
 
Track 2. Chronic care 
 
Milestone 4.3.05. Design emergency triggers 
and algorithms for chronic care 
The acute hyper- and hypoglycaemic emergencies 
related to diabetes are much more common in 
hospital or care settings. As for Milestone 4.3.02 
the morbidity and costs are high, and there is 
potential for mortality, particularly in elderly 
patients. These emergencies are similarly much 
better treated by standardised algorithms (across 
regions, countries and continents) and with 
specialist input in consultation. Designing, agreeing 
and implementing these algorithms on a wider 
scale is a research challenge, particularly for the 
neglected areas of chronic care outside the acute 
hospital setting. 
 
Milestone 4.3.06. Study prospectively the 
interaction between diet, activity and 
concurrent medication on progression and 
control of diabetes. This Milestone is concerned 
with studying the evolution of and progression to 
diabetes in patients in chronic institutional care, 
where the risk is higher and factors contributing 
need greater study. The issues in chronic care are 
somewhat different to those in the acute setting and 
it is essential that they are not neglected. 
 
Milestone 4.3.07. Test and validate new 
treatments: chronic care 
Given the high prevalence of diabetes in patients in 
hospital or long-term institutional care, there is an 
opportunity to design a whole range of new trials in 
these populations (see also Milestone 4.3.04). 
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Goal. 4.4. Achieve remission of diabetes and improvement of quality of life for 
obesity-related diabetes 
 
 
  Roadblock 3. Practical and ethical challenges of locating research participants among diverse groups 
  Roadblock 7. Lack of specific bioinformatic software to analyse and integrate multiple data on biological (genetic),  
   psychological, lifestyle and social factors  
  Roadblock 9. Lack of appropriate professional training and education 
 
 
 
Introduction and background 
Bariatric surgery is the most effective treatment for 
obesity resulting in long-term weight loss and 
amelioration of obesity-associated co-morbidities, 
particularly type 2 diabetes. Surgical therapies, 
apart from offering morbidly obese patients the best 
hope for substantial and sustainable weight loss, 
may lead to a reduction in morbidity and mortality. 
Metabolic benefits of bariatric surgery occur rapidly 
and independently of the weight loss and are 
correlated with the particular anatomical 
restructuring of the surgery.  
 
Understanding the mechanisms mediating the 
beneficial outcomes of bariatric surgery could result 
in new non-surgical treatment strategies for obesity 
and type 2 diabetes. The physiological issues 
associated with bariatric surgery and diabetes 
remission have yet to be clarified, and insight gained 
from such research would be useful for the 
development of new pharmacotherapy for the 
treatment of obesity and diabetes (see also 
Milestone 3.1.06). 
 
The number of morbidly obese patients BMI ≥ 40) 
requesting surgical treatment is increasing. While 
new surgical procedures are being developed there 
is the need to ensure a low post-operative mortality 
rate, that quality of life is enhanced and that the 
treatment is cost-effective. Bariatric surgery needs 
to be developed as a cost-effective and sustainable 
treatment that can be supported by national health 
services especially as obesity is more prevalent in 
underdeveloped countries and affects more people 
at lower socioeconomic levels. 
 
Types of bariatric surgery 
The field of bariatric surgical procedures consists of 
three major approaches. The first surgical approach, 
called restrictive, is aimed at decreasing the 
patient's caloric intake. Examples of restrictive 
surgery are the vertical banded gastroplasty and 
laparoscopic adjustable gastric band procedures, 
which only restrict stomach size. The second 
approach, called malabsorptive, is aimed at 
decreasing the absorption of nutrients. Jejunoileal 
bypass, which is rarely used today, and 
biliopancreatic diversion, with or without duodenal 
switch procedures belong to the malabsorptive 
category. More complicated surgeries combine both 
restrictive and malabsorptive principles and fall 
under the third category, combination surgery; 
Roux-en-Y gastric bypass, or simply gastric bypass, 
is the most common type of combination bariatric 
surgery performed and the one demonstrating the 
most robust metabolic effects.  
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Milestone 4.4.01. Understand glucose 
metabolism from the intestine after bariatric 
surgery 
During bariatric surgery, bowel segments are re-
routed and a substantial portion of the stomach is 
removed. Nutrients from the stomach are diverted 
from the proximal portion of the intestine to a more 
distal portion; thus, digestive physiology is altered 
significantly by excluding ingested nutrients from the 
upper intestine.  
 
Key enzymes for gluconeogenesis are expressed in 
the small intestine where they are induced in states 
of energy deficit. The resulting intestinal glucose 
production apparently activates portal-vein glucose 
sensors to engage a neurocircuit that increases 
hepatic insulin sensitivity and decreases hepatic 
glucose output. Furthermore, sensors in the liver 
may detect the elevated glucose and send an 
appetite-suppressing signal to the brain, which 
contributes to the satiety and weight loss seen with 
gastric bypass. Research is required both in animals 
and particularly in human subjects to understand 
better the effects of these surgical procedures on 
glucose and fat metabolism (see also Milestone 
3.1.06). 
 
The gut is now known to act as a large endocrine 
organ, producing hormones that have important 
sensing and signalling roles in the regulation of 
appetite and energy homeostasis. Potential 
mechanisms underlying the direct antidiabetic 
impact of bariatric surgery may include modulated 
nutrient stimulation of lower intestinal hormones 
(e.g. glucagon-like peptide 1), compromised ghrelin 
secretion and other hormones apart from the 
aforementioned such as peptide YY, oxyntomodulin, 
glucose-dependent insulinotropic polypeptide, 
cholecystokinin and pancreatic polypeptide, 
modulations of intestinal nutrient sensing and 
regulation of insulin sensitivity, and other changes 
yet to be fully characterised.  
 
These changes cause corresponding alterations in 
brain centres, such as the hypothalamus, which is 
responsible for energy homeostasis, and through 
these higher centres, hormones regulate long-term 
changes in energy stores. Apart from the hormones, 
variations in nutrient content may influence such 
interactions. So far, reports of the effect of different 
surgical procedures on these hormones have been 
controversial. Differences in surgical technique, 
research methodologies, blood collection time points 
and sample assays as well as sample processing 
could account for discrepancies in the literature. The 
use of standardised protocols would limit such 
pitfalls and further clarify the effect of surgery itself 
on the circulating levels of gut hormones. 
 
Questions remain regarding the lipid-carbohydrate 
based neurocircuits that influence hepatic glucose 
production, the response to intestinal nutrient 
sensing and metabolism as well as the way in which 
these pathways are affected by intestinal bypass. 
Research aimed at determining the relative 
importance of the physiology of brain-liver-intestine 
crosstalk and at identifying additional mechanisms 
promises not only to improve surgical design but 
also to identify novel targets for the treatment of 
diabetes (see also basic research proposed in 
Chapter 3). 
 
Milestone 4.4.02. Characterise patients who will 
benefit from surgical treatment and establish 
guidelines for perioperative safety  
According to the 1991 National Institutes of Health 
(NIH) consensus conference on gastrointestinal 
surgery for severe obesity, patients are candidates 
for surgery if they are morbidly obese (BMI>40 
kg/m2 or >35 kg/m2 with co-morbidities), have failed 
attempts at diet and exercise, are motivated and 
well informed, and are free of significant 
psychological disease. 
 
Current evidence suggests that surgical therapies 
offer the morbidly obese the best hope for 
substantial and sustainable weight loss. Minimally 
invasive methods currently available have increased 
the demand for bariatric procedures. Comparative 
data indicate that procedures with more dramatic 
clinical benefits carry greater risks, with those 
offering greater safety and flexibility being 
associated with less reliable efficacy. However, no 
evidence-based clinical reviews so far exist to guide 
patients and surgeons in selecting the bariatric 
surgical technique most applicable to a given patient 
in a given situation. For this reason existing 
techniques must be reviewed and graded as to their 
level of evidence before they can be recommended.  
 
Patient selection algorithms should favour individual 
risk:benefit and quality-of-life considerations over 
traditional anthropometric and demographic figures. 
Bariatric care should be delivered within 
credentialed multidisciplinary environments. All 
bariatric surgical techniques including laparoscopic 
Roux-en-Y gastric bypass, adjustable gastric 
banding, biliopancreatic diversion with duodenal 
switch, and primary laparoscopic sleeve 
gastrectomy, have been proven effective. Currently, 
the choice of operation is driven by patient and 
surgeon preferences. 
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Obesity has also a significant adverse impact on 
reproductive outcome. It influences not only the 
possibility of conception but also the response to 
fertility treatment, and increases the risk of 
miscarriage, congenital anomalies and pregnancy 
complications in addition to potential adverse effects 
on long-term health of both mother and infant (see 
also Milestone 4.7.03). Women should aim for a BMI 
in the normal range before starting any form of 
fertility treatment, and a weight reduction to a BMI of 
less than 30 kg/m2 is preferable before pregnancy. 
The effect of bariatric surgery in achieving a weight 
reduction that will affect fertility has not been 
evaluated and guidelines are needed for the follow-
up of fertility after bariatric surgery. Moreover 
studies are needed on the outcome of pregnancies 
following bariatric surgery weight loss. 
Recommendations for surgical intervention in 
morbidly obese women are lacking.  
 
Obesity rates are increasing among children and 
adolescents. However, ethical issues for bariatric 
surgery in these age groups remain to be resolved, 
and more studies are needed to investigate the 
efficacy and safety of bariatric surgery in younger 
ages. The concept of major obesity surgery for very 
young patients is hugely controversial, and there 
have been no studies to date to provide a basis on 
which intermediate and long-term risks can be 
assessed. The effects of bariatric surgery on growth 
and fertility need to be investigated further. 
 
Bariatric surgery is not benign, and patients 
experience the same risks as anyone undergoing 
major surgery; however, it has to be proven 
relatively safe for patients who would normally be 
considered high-risk, and the low mortality rate 
should be reassuring. These parameters (surgical 
morbidity and mortality as well as efficacy) require 
formal prospective study in people of older age who 
are more likely to have additional cardiometabolic 
risk factors. 
 
Milestone 4.4.03. Evaluate short-term outcomes 
for bariatric surgery  
Major adverse events following surgery, some 
necessitating reoperation, include anastomosis 
leakage, pneumonia, pulmonary embolism, band 
slippage and band erosion. Improvement of surgical 
procedures, mastering of the techniques and close 
collaboration of the relevant specialists should be 
aimed for.  
 
Postoperative support groups are an important part 
of a bariatric programme and may help to improve 
postoperative results and limit relapse. Thus one 
important research topic is the study of the effect of 
patient support groups and education on 
postoperative results.  
The institutional needs of a bariatric programme 
extend across outpatient and inpatient 
environments, and the entire environment and 
facilities should be appropriate and comfortable for 
patients with morbid and supermorbid obesity; such 
design should be evidence-based to achieve the 
best results. Healthcare providers and staff who 
work with bariatric patients should undergo training 
to specialise in this area and meet the needs of this 
particular group of patients (see also Milestone 
4.2.05).  
 
Milestone 4.4.04. Evaluate long-term outcomes 
for bariatric surgery  
Despite a large increase in bariatric surgery, the 
number of operations performed is still far less than 
the number of morbidly obese patients. Many 
factors, such as patient and provider attitudes 
towards obesity and bariatric surgery, cost, and 
health insurance coverage, contribute to the low 
uptake of surgery as a method for weight reduction 
and even more for diabetes remission. In turn, these 
issues will likely lead to disparity across the 
European region. 
 
Mixed attitudes toward bariatric surgery are found in 
the literature with patient perception that it is a 
dangerous and extreme measure. The overall 
attitude of patients and providers toward bariatric 
surgery is inconsistent and more prospective 
research is required to provide evidence of the 
efficacy and safety of these procedures. Key factors 
in patient safety include comprehensive 
preoperative evaluation, use of appropriate and 
reliable evaluation instruments, and the 
development of short- and long-term treatment 
plans. 
 
Standardised, randomised studies need to be 
designed and implemented to include analysis of 
postoperative mortality and morbidity, change in 
obesity-related co-morbidities (type 2 diabetes, 
hypertension, lipid disorders, cardiovascular risk) 
and other adverse events. 
 
Milestone 4.4.05. Evaluate psychosocial follow-
up of patients undergoing bariatric surgery 
Success following bariatric surgery should not only 
include weight loss and improvement or cure of co-
morbid conditions but also improve eating 
behaviour, quality of life and a range of psychosocial 
variables. Unfortunately, bariatric surgery does not 
lead to identical results in each patient. Patients who 
fail to adjust their eating behaviour and lifestyle after 
surgery may experience adverse reactions. 
Compliance and adjustment may be attributed 
largely to psychological factors, implying that the 
operation on its own represents only one element in 
the treatment of severe or morbid obesity. 
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Considering the role of psychosocial factors on the 
outcomes of the surgery and the impact of the 
operation on the psychological and social situation, 
mental health professionals should participate in the 
process of evaluation and treatment. Psychological 
evaluation of the patient before weight loss surgery 
is essential because of the prevalence of psychiatric 
co-morbidities in people with severe obesity and the 
behavioural adaptations required for successful 
surgical outcomes. Although there is currently no 
international standard for the specific components of 
these evaluations, there is general agreement in the 
literature about the objectives and the kinds of 
assessment methods that are most useful. Further 
research is needed to evaluate the appropriate 
methodology to be applied in such patients. It may 
be that it is more important to focus on improving 
postoperative support instead of searching for only 
technical surgical outcome predictors.  
 
Uncontrolled eating and grazing have been 
identified as two high-risk eating patterns after 
surgery. Clearer characterisation of favourable and 
unfavourable postsurgical eating behaviours, 
reliable methods to assess their presence, and 
empirically tested postsurgical intervention 
strategies are required to optimise weight loss 
outcomes and facilitate psychological well-being in 
at-risk groups. 
 
Reconstructive surgery following weight loss after 
bariatric surgery results in a significant improvement 
in overall quality of life. Reconstructive surgery 
should be incorporated in the multidisciplinary care 
programme following weight loss surgery in the 
morbidly obese patient in order to improve the 
psychosocial outcome of bariatric surgery and must 
be included in costing. However, increased costs 
may exacerbate further differences between 
countries across Europe, including the 27 European 
Union Member States.  
 
Milestone 4.4.06. Evaluate cost-effectiveness of 
bariatric surgical intervention  
Although bariatric surgery has been shown to be 
effective in reducing body weight in most morbidly 
obese patients, it remains to be proven that it also 
results in greater quality of life and decreased 
healthcare costs for patients and for the healthcare 
system. 
 
All bariatric surgical techniques, both open and 
laparoscopic, in widespread current use must be 
studied and be compared with each other and with 
non-surgical interventions. All age groups and BMI 
measures of weight change, quality of life, 
perioperative and postoperative mortality and 
morbidity, change in obesity-related co-morbidities 
and adverse events should be studied. Full cost-
effectiveness analyses, cost-utility analyses, cost-
benefit analyses and cost-consequence analyses 
have to be evaluated and economic modelling 
needs to be developed.  
 
Uncertainties remain and further research is 
required to provide detailed data on patient quality 
of life; impact of surgeon experience on outcome; 
late complications leading to reoperation; duration of 
co-morbidity remission, and resource use. 
Randomised controlled trials are appropriate to 
provide evidence on bariatric surgery for young 
people and for adults with Class I (BMI 30-34.9 
kg/m2), Class II (BMI 35-39.9 kg/m2) and Class III 
(BMI 40 kg/m2 and above) obesity. New research 
must report on the resolution and/or development of 
co-morbidities such as type 2 diabetes and 
hypertension so that the potential benefits of early 
intervention can be assessed. 
 
Studies that prove the benefits and cost-
effectiveness of bariatric surgery should influence 
national healthcare systems for the financial 
coverage of people in most need. Age- and BMI-
based candidacy guidelines should not limit access 
for patients experiencing progressive or poorly 
controlled obesity-related co-morbidities if the risk: 
benefit analysis favours surgery. A multi-track 
approach to treatment across Europe should be 
established for people who have undergone surgery 
as well as for poorer patients in those countries 
where people cannot afford this treatment. 
 
Milestone 4.4.07. Identify and certify centres of 
excellence to carry out surgical interventions to 
treat diabetes 
The issue of ‘health tourism’ should be addressed 
by ensuring that all centres, regardless of location, 
are identified and validated as being approved to 
carry out surgery for obesity. Such data could be 
collected and monitored by the EPCRD (see also 
Goal 4.1). This would reduce possibilities of 
incorrect treatment and lack of follow-up on the 
patient’s return to their country of residence if the 
surgery is carried out abroad. 
 
Milestone 4.4.08. Develop evidence-based 
guidelines for surgical approaches to treat 
obesity-related diabetes  
Gastrointestinal operations are now being used 
worldwide to treat diabetes in association with 
obesity, and increasingly, for diabetes alone. 
However, the role for surgery in diabetes treatment 
is not clearly defined and there are neither clear 
guidelines for these practices nor sufficient plans for 
clinical trials to evaluate the risks and benefits of 
such ‘diabetes surgery’, and the duration of 
remission of diabetes is not yet known. Clinical trials 
to investigate the exact role of surgery in patients 
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with less severe obesity and diabetes are a priority 
before bariatric surgery is considered a therapeutic 
tool for diabetes. Before prospectively collected 
comparative data among the different bariatric 
operations are available it remains impossible to 
make definitive recommendations for one procedure 
over another. Randomised controlled comparative 
clinical trials need to be performed in order to 
evaluate long-term effects of the bariatric surgery, 
before its use in younger ages and specifically in 
children.  
 
Milestone 4.4.09. Develop pharmacologic 
interventions that mimic the effect of surgical 
intervention to treat or prevent diabetes  
Research to elucidate mechanisms through which 
diabetes remission is achieved with bariatric surgery 
should facilitate the design of new drugs to treat and 
prevent diabetes. Mounting evidence indicates that 
certain operations involving intestinal diversions 
improve glucose homeostasis through varied 
mechanisms beyond reduced food intake and body 
weight, for example by modulating gut hormones. 
Surgery-specific, weight-loss-independent effects of 
bariatric surgery on fast remission of type 2 diabetes 
and glucose homeostasis also include altered 
physiology from excluding ingested nutrients from 
the upper intestine and enhanced nutrient 
stimulation of the lower intestine hormones. These 
processes modulate intestinal nutrient sensing and 
regulation of insulin secretion and insulin sensitivity 
along with other changes yet to be fully 
characterised. 
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Goal 4.5. Achieve normal ageing in diabetes with preserved quality of life 
 
 
   Roadblock 3. Practical and ethical challenges of locating research participants among diverse groups 
   Roadblock 4. Lack of birth cohorts and registries with repeated examinations for long-term follow-up studies over  
    the life-course  
   Roadblock 7. Lack of specific bioinformatic software to analyse and integrate multiple data on biological (genetic),  
    psychological, lifestyle and social factors 
 
 
 
Introduction and background 
Europe has a rapidly growing ageing population 
with increased mean life expectancy. These older 
individuals become much more prone to a range of 
chronic diseases, including diabetes, especially 
type 2 diabetes. There is a well-documented gap in 
life expectancy between people who develop 
diabetes and healthy people of similar age. 
Diabetes itself can be considered a disease of 
premature ageing, specifically of the cardiovascular 
system and also of other tissue and organ systems, 
at least in a substantial proportion of patients. 
However, some patients appear to be protected 
against this accelerated ageing process, and the 
underlying mechanisms of these protective 
processes remain unclear. 
 
A European research strategy for ageing and 
diabetes is likely to include: experimental studies in 
animals to investigate biomedical aspects of the 
normal ageing process, as well as in diabetes; 
studies in people without diabetes; studies in 
people with diabetes of short-, intermediate- and 
long-duration to investigate the process of ageing in 
different organs. The impact of diabetes treatments 
specifically on these ageing processes is also a 
research priority. Thus, specific studies of biological 
and molecular ageing in patients treated with the 
traditional oral hypoglycaemic agents, insulins, as 
well as the wide range of newer agents, are 
required. The risk of cancer (an age-related 
phenomenon in general) in relation to diabetes is 
an area of growing interest as diabetes itself as well 
as some drugs used for the treatment of diabetes 
may also impact on the cancer risk and the 
modification of this risk (see also Milestones 3.1.10, 
3.2.04, 4.11.04, 6.1.01, 6.1.06, 6.4.03 and Goals 
3.4, 4.3, 4.6, 4.9).  
 
Milestone 4.5.01. Understand normal ageing in a 
life-course perspective 
The biological process of ageing starts early in life, 
at the time of conception since genetic factors are 
important in shaping organ development and rate of 
ageing. One measure of this is telomere length, 
which is determined in utero and shortens with 
every cell division. Therefore the telomere length is 
a marker of biological ageing that can be 
determined in adult life, preferably at several time 
points. Subjects with a faster telomere attrition rate 
are supposed to have a more rapid biological 
ageing. In addition, a number of studies have 
shown the programming effect of fetal growth 
patterns resulting for some children in a state of 
small for gestational age at birth. If this condition is 
combined with a rapid catch-up growth in postnatal 
life the risk of age-related diseases in adult life is 
increased, for example cardiovascular disease and 
type 2 diabetes. If however, fetal and early post-
natal life development is normal, conditions favour 
normal biological development and ageing (see 
also Goal 2.1). 
 
Recently, new evidence has shown that cognitive 
function in early life is a factor of importance to 
influence the life-course and patterns of ageing. 
Cognitive function is shaped not only by genetics 
and early life growth, but also by socio-cultural 
factors during childhood and adolescence. Normal 
ageing is thought to be facilitated by normal 
cognitive function, good nutrition and lack of 
adverse psychosocial factors. The latter could be 
evaluated repeatedly during the life-course, thus 
contributing to a better understanding of how the 
social and psychosocial environment interacts with 
genetic and early life factors for shaping the 
biological ageing (such as gene-environmental 
interactions, epigenetics). 
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Milestone 4.5.02. Understand normal vs 
accelerated ageing in relation to diabetes 
The process of ageing in humans is shaped by 
evolutionary selection, but many aspects of ageing 
are still poorly understood, especially in a chronic 
disease state such as diabetes. The first Goal is 
therefore to understand the ageing process in 
general (Milestone 4.5.01), but also specifically in 
diabetes (Milestone 4.5.02). There are examples of 
ageing in different organs that can be used as a 
focus for research in diabetes; these include the 
brain and the risk of age-dependent cognitive 
decline and development of dementia, both of the 
vascular type and Alzheimer´s dementia (see also 
Goal 4.9). Another example is the ageing of the 
vessel wall, as it applies to arteries (arterial 
stiffening, arteriosclerosis, and atherosclerosis, or 
the venous vessels increasing the risk of thrombo-
embolism, see also Goal 6.1). 
 
As many people with diabetes face a decreased 
lifespan and an increased burden of disease and 
co-morbidities, it is important to delineate the 
consequence of accelerated normal ageing in these 
patients and what is added to that in the form of 
diabetes-specific influences on the ageing process. 
This could be measured by the way 
hyperglycaemia-related molecules [glycated 
proteins, advanced glycated end-products (AGES) 
etc] interact with different biological tissues, e.g. in 
the lungs or in the arterial wall, or by the way 
telomere length is shortened in patients with 
diabetes (both type 1 and type 2) with or without 
cardiovascular disease, such as myocardial 
infarction. 
 
Milestone 4.5.03. Define markers and predictors 
of early ageing 
Ageing is ultimately based on the interaction 
between genes and the environment (e.g. 
hyperglycaemia). One of the consequences of 
diabetes is a process of early (accelerated) ageing 
of organs that is different from healthy ageing and 
is also a measurable process.  
 
Longstanding hyperglycaemia causes glycation of 
tissues. This process resembles ageing due to
oxidative stress and chronic inflammation. The 
principal complications of diabetes occur in 
vascular tissues and diabetes can be considered as 
a disease of early vascular ageing. It is equally 
important to understand why certain patients can 
withstand many years of diabetes with no vascular 
complications. Some cohort studies of this 
phenomenon have been initiated and are a high 
priority for the elucidation of factors protective 
against the ageing process.  
 
It has been shown that subjects with type 2 
diabetes have shorter telomeres than people 
without diabetes and that even shorter telomeres 
could be found when diabetes is combined with 
myocardial infarction. Telomeres form the cap of 
the DNA helix and are shortened with every cell 
division and represent a molecular marker of 
ageing. Research in telomere biology in patients 
with diabetes is therefore needed to better 
understand these aspects of the ageing process.  
 
Milestone 4.5.04. Develop strategies to prevent 
or treat accelerated ageing in diabetes 
Research on progression of ageing in diabetes will 
require specific studies of the effects of a range of 
interventions on markers of ageing (see also Goal 
3.1):  lifestyle interventions (diet, exercise, smoking 
cessation); functional foods (food constituents that 
may decrease postprandial hyperglycaemia or 
protect from oxidative stress); drug treatments (for 
glycaemia but also for other aspects of the vascular 
ageing process such as endothelial dysfunction and 
AGE-breakers, to stop the glycation of proteins in 
various organs); technology applications (e.g. for 
counteracting vascular changes before 
complications occur); analysis of compliance with 
the above treatments and the impact of self-care 
strategies on the ageing process. 
 
Milestone 4.5.05. Evaluate cost-effectiveness of 
strategies to promote normal ageing in diabetes  
New methods for modelling the cost of diabetes 
and its complications should be further developed, 
preferably based on large cohorts or national or 
even international registers of treated patients with 
diabetes (see also Goal 4.1). 
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Goal 4.6. Improve metabolic and psychological endpoints in paediatric diabetes 
 
 
  Roadblock 5. Lack of large European diabetes networks 
  Roadblock 7. Lack of specific bioinformatic software to analyse and integrate multiple data on biological (genetic),  
  psychological, lifestyle and social factors  
  Roadblock 11. Drug regulatory issues: paediatric drug approvals lag behind adult decision-making 
  Roadblock 12. Partnerships between academia and industry (both pharmaceutical and other industry) are needed 
  Roadblock 13. Huge differences in structure, process, quality and delivery of diabetes care between European   
   countries  
  Roadblock 14. Advances in diabetes treatment or new drugs or new devices can only be implemented if society is  
  able to support such treatments  
 
 
 
Introduction and background 
Adolescents with type 1 and type 2 diabetes are 
particularly prone to poor metabolic and 
psychosocial outcomes due to the potentially long 
diabetes duration they will face. At the same time 
the study of the effect of diabetes in this age group 
provides an opportunity to study early vascular 
ageing without other concomitant diseases. 
Successful ageing with diabetes starts in childhood 
as many processes leading to debilitating 
complications later in life have their onset in 
childhood. This offers a unique opportunity to 
identify potential factors that are important to delay 
accelerated biological ageing in diabetes. Also, 
preventive strategies that prove effective in 
childhood and adolescence are likely to be 
particularly cost-effective as most of the healthcare 
cost is incurred for the treatment of late 
complications. 
 
There is a predicted 70 percent increase in 
prevalence of diabetes by 2020 with more and 
more young children being affected. These children 
show a more rapid decrease in beta cell function 
and have less residual insulin production than 
adolescents or adults. The average metabolic 
outcomes of children with diabetes as judged by 
international cohort studies of HbA1c were found to 
be significantly worse than in the adult population, 
with those of adolescents being the worst. Also, 
studies with new technologies such as continuous 
glucose monitoring have shown a less favourable 
effect in youth compared to adults.  
 
Implementation of new technologies has to be seen 
in the context of family and peer group influence 
and the absence of complex decision-making by 
the patients themselves. In addition, lifestyles of 
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young children who have a long overnight sleep as 
well as unpredictable activity and eating behaviour 
have to be considered. The age-dependent 
changes of insulin sensitivity (being highest in 
young children and lowest during puberty) or the 
influence of frequent infectious diseases are further 
challenges to achieve outcomes comparable to 
adults. 
 
Normal psychosocial development of children 
requires that diabetes management allows flexibility 
with informed self-management. However with 
current therapies, children are often forced onto 
restrictive treatment regimens and face 
discrimination in school and among peers. Studies 
in the UK and Scandinavia confirm higher mortality 
rates in all paediatric age groups with diabetes 
compared to healthy children. Children and young 
people with diabetes are at risk of developing 
serious disabling complications similar to adults. In 
addition, long-term research shows that poor 
control during the early years of the disease has a 
major impact on the long-term prognosis despite 
better control thereafter (so-called ‘metabolic 
memory’); this makes it imperative to improve 
outcomes in this age group.  
 
Unfortunately there are still many differences in 
access to diabetes care and treatment across 
Europe. Studies involving 18 paediatric diabetes 
centres from 12 European Union Member States 
plus Switzerland and Norway revealed significant 
outcome differences among these centres 
indicating the need to find a way to share best 
practices. 
 
Special emphasis has to be put on the transition 
from paediatric to adult care. Organisation of 
paediatric and adult care is not continuous in many 
European Union states. Models ensuring an 
effective transfer into adult care are needed for a 
long-term preservation of the potential benefits from 
improved paediatric diabetes care. 
 
Successful implementation of this road map would 
improve the situation for children with diabetes in 
Europe and ensure that all children have the right to 
participate fully in all the experiences of childhood 
and adolescence, regardless of whether they have 
diabetes and wherever they live. Also it will reduce 
the effects of accelerated vascular ageing imposed 
by the diabetic state and provide the basis for a 
long-term participation in professional and family 
life without, or with delayed debilitating long-term 
diabetes complications (see also Milestone 1.5.09 
and Goals 4.1, 4.5). 
 
Due to the comparatively small patient numbers in 
paediatric diabetes (both type 1 and type 2 
diabetes) appropriately powered clinical studies 
require a multi-centre framework. Thus, 
independent funding for collaborative research 
infrastructure and continuity is urgently needed.  
 
Track 1: Paediatric research infrastructure 
 
Milestone 4.6.01. Create a paediatric database 
for benchmarking, registry and clinical trial 
recruitment  
A prerequisite for clinical research is a good 
database. To identify patients eligible for trials or to 
compare outcomes between different centres, a 
common data set needs to be developed. The 
World Health Organization (WHO) paediatric data 
set was developed nearly 20 years ago as part of 
the St. Vincent declaration initiative. On a European 
level much progress has been made regarding 
health indicators and diabetes epidemiology (for 
example EUBIROD, European Best Information 
through Regional Outcomes in Diabetes, supported 
by the European Commission DG SANCO), so that 
this WHO data set is now outdated. An improved 
universal dataset is required as well as an 
information technology infrastructure to exchange 
such data between centres (see also Goal 4.1). 
 
Milestone 4.6.02. Develop a clinical staging 
system for paediatric diabetes within this 
database 
Both type 1 and type 2 diabetes in children 
develops in different phases from the initial genetic 
predisposition, with subclinical metabolic changes 
(and immunological processes such as antibody 
development, particularly in type 1 diabetes) 
preceding overt clinical diabetes (during which 
typically the diagnosis is made in the majority of the 
cases), often followed by a partial remission phase 
when some of the residual beta cell function is 
temporarily restored after the onset of treatment. 
After complete beta cell failure (not all paediatric 
patients actually reach this stage) insulin 
substitution is necessary leading to a more unstable 
metabolic state.  
 
The rate of progression from one stage to another 
is age-dependent. In type 1 diabetes, diabetes-
associated antibodies are often already found 
within the first two years of life, while clinical 
diabetes is diagnosed on average at 11 years. 
Children with diabetes onset in the preschool age, 
i.e. more rapid progressive disease, have less 
residual beta cell function than those diagnosed in 
adolescence. 
 
Not all interventions and therapeutic procedures will 
be similarly effective in different phases of diabetes. 
Procedures aiming at restoration or preservation of 
beta cell function need staging by genetic, 
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biochemical and clinical parameters. Such 
assessment should replace what we now call 
‘remission phase’ (Honeymoon phase) or 
prediabetes in children. This staging system would 
allow development of strategies aimed at primary 
prevention (for those at increased genetic risk), 
secondary prevention (for those with subclinical 
abnormalities) and tertiary prevention of late 
complications in full-blown disease.  
 
The development of large clinical databases 
including data on genetic background, 
immunological features and clinical course of the 
disease (for example changes in residual beta cell 
function over time) is a prerequisite for developing 
and testing such a clinical staging system. Ideally it 
could be combined with a biobank to link clinical 
data with biomarkers. Subsequently, it would be 
used to monitor the interventions described in the 
other tracks. 
 
Track 2. Systematic healthcare delivery in 
paediatrics 
 
Milestone 4.6.03. Compare in-patient and out-
patient approaches 
Differences between leading paediatric diabetes 
centres are present during both the early and later 
stages of the disease. There is increasing evidence 
that the early course of diabetes during the first 
year of clinical diabetes has a huge impact on the 
later metabolic results (metabolic memory) and 
psychosocial coping with the chronic disease.  
 
One major difference between the initial 
approaches to paediatric diabetes is that some 
health systems prefer an initial in-patient training 
phase compared to a system of outpatient 
education at onset. The limited study data have 
focussed only on short-term outcomes and have 
not aimed at more ambitious metabolic targets that 
are currently recommended also for the young age 
group. This initial phase of diabetes care requires 
further prospective study on a large scale.  
 
Milestone 4.6.04. Assess effectiveness of 
national paediatric diabetes programmes at a 
European level 
The status report of children with diabetes in 
Europe identifies several shortcomings in 
epidemiological and health outcomes research in 
Europe. For example epidemiological data are 
collected often only for younger children. Thus, only 
five of the 27 European Union Member States have 
data for the 15-18-year age group. Also, only 13 out 
of 25 countries have reported a national paediatric 
diabetes register. Presently, only seven countries 
have a national plan or special provisions 
addressing children with diabetes and 16 out of 25 
countries have recognised paediatric diabetes 
centres. Exchange of information between centres 
of reference for paediatric diabetes is crucial to 
implementing advances of paediatric diabetes 
therapy. Health technology assessments as well as 
comparisons of cross-border healthcare would 
allow the effects of varying national strategies of 
healthcare delivery to be evaluated. This line of 
research could be the basis for exchanging best 
practices and identifying cost-effective interventions 
in different health policy frameworks.  
 
Milestone 4.6.05. Investigate models for 
transition from paediatric to adult care 
There is a large heterogeneity of models for the 
transition from paediatric to adult care. The time 
point of such a transition ranges from school age to 
young adult (i.e. 21 years or older). Such different 
models need to be investigated for their 
effectiveness. As the transition period constitutes 
the period during which first complications can be 
detected and early intervention for micro- and 
macroangiopathy is likely to be more effective than 
later in life, this period deserves particular attention. 
Outcomes both in terms of clinical diabetes (such 
as glycaemic control, complications) as well as 
psychosocial goals (such as educational level, 
professional status, home making) have to be 
compared regarding structured and unstructured 
transition models and earlier and later transition in 
different healthcare delivery systems. Transition 
care for diabetes will thus require formal 
prospective study. 
 
Milestone 4.6.06. Monitor health economic 
impact of interventions 
A reporting system needs to be developed that 
allows the assessment of different health care 
interventions both at national and international 
levels. Currently health economics data are lacking 
in paediatric diabetology and need to be coupled 
with clinical outcomes. The status report of 
paediatric diabetes within the SWEET project 
identified significant differences between countries 
with respect to access to specialised healthcare 
teams and modern therapies (insulin analogues, 
insulin pumps, glucose sensors). To finance the 
advances of translational research for the most 
vulnerable population such data need to be 
generated and updated regularly. Combining the 
clinical paediatric data set (see also Milestone 
4.6.01) with health economics data will make it 
possible to evaluate the cost-effectiveness of trends 
in risk factor control, equity and the quality of 
paediatric diabetes healthcare services.  
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Track 2. Psychosocial intervention  
 
Milestone 4.6.07. Identify children at increased 
risk of poor outcomes 
Family structures are rapidly changing across 
Europe. Comparative research of good and poor 
outcomes in paediatric diabetes has identified 
family function as extremely important for achieving 
good outcomes. When the basic methods for 
following up patients with paediatric diabetes are 
established in a multi-centre international fashion, 
sub-groups of children with certain genetic markers, 
biomarkers, psychosocial factors or influences of 
early childhood can be studied. Currently little is 
known as to how to tailor diabetes healthcare 
delivery to different family structures (such as single 
parent and ‘patchwork’ families) or parenting 
strategies, in terms of their influence on the long-
term metabolic and psychosocial outcomes. 
Different therapeutic, educational, psycho-
interventional strategies have to be tested in proper 
controlled trials once such children at increased risk 
of poor longitudinal outcomes have been identified. 
 
Milestone 4.6.08. Evaluate models to reach 
families at risk with age-appropriate education  
Diabetes education of children and families is 
essential for achieving better outcomes. However, 
little research is available to compare different 
strategies for delivering age-appropriate education. 
Furthermore, these educational interventions need 
to be tested within different social and cultural 
backgrounds (see also Milestone 4.2.04). 
Particularly with new technological advances, it will 
be necessary to identify approaches in the 
paediatric age group that are as effective as in 
adults.  
 
Milestone 4.6.09. Understand the role of 
diet/normal eating for achieving good outcomes 
A prerequisite for successful diabetes therapy is to 
adjust it to food. For example, the insulin dose and 
action profile needs to be balanced against the 
expected carbohydrate intake. There are several 
areas of controversy: the quantification of 
carbohydrate (e.g. grams, exchanges, 
portions/servings) or the influence of other nutrients 
on glycaemic control and long-term prognosis (e.g. 
fat, fibre, sucrose). In addition, so far no structured 
research has addressed the impact and 
psychological effect of dietary counselling methods. 
It is well known that adult eating behaviour is 
developed during childhood. Therefore, a better 
evidence base for such strategies could have a 
long-term effect on patient-oriented outcomes, both 
in paediatric and adult care.  
 
Milestone 4.6.10. Test and validate new 
interventions successfully in clinical trials 
Paediatric trials of new interventions need to look at 
patient-oriented outcomes that are relevant to age. 
For example, endpoints such as debilitating 
complications are not appropriate for the paediatric 
age group. Meaningful endpoints may include 
psychosocial variables such as maintaining a family 
structure, coping of parents or achieving positive 
school outcomes. Such innovative trial designs 
need to be evaluated to test new interventions in 
paediatric trials.  
 
Track 3: New paediatric drugs and devices 
 
Milestone 4.6.11. Evaluate paediatric use of 
drugs and devices  
Several new drugs i.e. new insulins and drugs for 
treatment of type 2 diabetes have become 
available, with more expected in the near future. 
These may become of special value for younger 
patients. For example, incretins may not only offer 
novel approaches for adult type 2 diabetes but may 
even be effective in the prediabetic stage often 
encountered in obese adolescents. In type 1 
diabetes more rapid-acting insulins may allow an 
even better treatment of the rapid blood glucose 
swings regularly encountered in the young age 
group, particularly with the closed-loop or semi-
closed-loop delivery systems currently under 
development. Randomised controlled trials of 
continuous glucose monitoring have shown that 
patients in the paediatric age group are less likely 
to wear such devices continuously than adults and 
show poorer metabolic outcomes. This indicates 
that the current arsenal of insulins and devices is 
inadequate to tailor satisfactory insulin regimens. 
Also drugs to restore or preserve residual beta cell 
function need to be evaluated depending on the 
clinical stage of the disease. Randomised 
controlled trials looking at the effects on both 
metabolic outcomes as well as on the psychosocial 
development and quality of life of children and 
family are necessary to make the appropriate 
decisions for the allocation of healthcare resources. 
At present most paediatric studies are limited to 
paediatric investigational plans needed for 
regulatory submission for drug approval by the 
European Medicines Agency (EMA). Disparities 
across Europe are likely regarding the achieved 
quality of life with diabetes and the potential effect 
that such new treatments and devices may have. 
Provisions for comparative research in this area are 
lacking. 
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Milestone 4.6.12. Develop monitoring/intelligent 
decision-making systems for remote treatment 
of children  
Recent study results with continuous glucose 
monitoring systems indicate less favourable 
outcomes for paediatric patients than adult patients. 
This suggests that such advanced technologies 
need to be coupled with parental or diabetologist 
supervision as many of the associated tasks 
interfere with normal life. As the self-motivation 
found in adults cannot be expected from children, 
special provisions for remote monitoring and 
treatment have to be put in place. Children tend to 
spend more and more time away from the core 
family in modern European societies. Therefore, 
systems for supervised diabetes care need to be 
developed for this age group. Different approaches 
need to be investigated into how parental 
supervision or adult decision-making can be 
provided to make these new technologies as 
effective in paediatric care as in adult life. 
 
Milestone 4.6.13. Test different approaches to 
diabetes education in novel therapies 
As with standard diabetes therapy, any new 
treatment strategy needs to be accompanied by an 
educational strategy. Although it is generally agreed 
that education in the paediatric age group needs to 
be tailored to age and cultural background, little 
comparative research evidence or data on cost-
effectiveness are available. Paediatric diabetes 
education needs to take into account not only the 
person with diabetes but also family members and 
other caregivers involved in the provision of care. 
Educational materials and programmes need to be 
tested for efficacy and cost-effectiveness. For 
example, individual teaching approaches have to 
be compared to group education or interactive 
Internet-based learning programmes. Also, the 
necessary time intervals for follow-up education 
have to be determined. 
 
Milestone 4.6.14. Evaluate additional risk 
reduction of new interventions 
Even if restoration of residual beta cell function is 
one day achievable even before onset of clinical 
symptoms of diabetes (see also Chapter 2), or 
technological advances on the road to the artificial 
pancreas (closed-loop system) become available 
also for paediatric patients, it is likely that such 
treatments will not be available to or successful in 
all patients. Despite the availability of novel 
strategies, certain sub-groups at risk for poor 
outcomes will remain. These patients who cannot 
be treated successfully with modern therapies need 
to be identified at a very early stage and treated 
with traditional approaches such as conventional 
insulin therapy.  
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Goal 4.7. Prevent pregnancy-related acute and long-term diabetes complications in 
both mother and child 
 
 
  Roadblock 2. Variation, lack of standardisation or international consensus across Europe in laboratory conditions,  
   measurement techniques, sample handling and clinical diagnoses and practice (including GDM)  
  Roadblock 3. Practical and ethical challenges of locating research participants among diverse groups 
  Roadblock 4. Lack of birth cohorts and registries with repeated examinations for long-term follow-up studies over  
   the life-course  
  Roadblock 13.  Huge differences in structure, process, quality and delivery of diabetes care between  
   European countries  
  Roadblock 15. Lack of appropriate animal models to study fetal programming, fetopathy and embryopathy 
 
 
 
Introduction and background 
Gestational diabetes mellitus (GDM) occurs in 5-15 
percent of pregnancies and is increasing in 
prevalence. Women with a history of GDM have a 
very high risk of developing type 2 diabetes (80 
percent within 5-10 years following pregnancy) and 
are also at increased risk for cardiovascular 
disease. However, prevention trials have shown 
that diet and exercise as well as pharmacological 
intervention can diminish the risk substantially (by 
50 percent). In addition to acute pregnancy-
associated complications (diabetic fetopathy) the 
offspring also have increased risk of obesity and 
metabolic syndrome in childhood and adolescence. 
Genetic predisposition, but also fetal programming 
and metabolic imprinting may contribute to these 
long-term risks in offspring. Genes and other 
factors contributing to fetal programming and 
metabolic imprinting, predisposing the offspring to 
obesity and diabetes in adulthood, are currently 
unknown as are factors underlying the different 
vulnerability of male and female offspring. 
 
Criteria for diagnosis of GDM differ across the world 
and optimal treatment strategies and blood glucose 
targets during pregnancy to avoid maternal and 
fetal complications are still not known. The efficacy 
of conventional and new oral antidiabetic drugs and 
that of glucagon-like peptide 1 analogues or 
receptor agonists during pregnancy and 
breastfeeding have not yet been studied. Folic acid 
dosage during pregnancy in diabetes, as well as 
the impact of iron supplementation, vitamin D and 
antioxidants, is controversial.  
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The mechanisms of diabetic embryopathy and 
fetopathy are unclear and thus better 
understanding of the underlying pathophysiology 
and the generation of the best evidence-based 
therapeutic strategies are required. The ultimate 
Goals are to: prevent gestational diabetes; achieve 
normal pregnancy outcomes in diabetic 
pregnancies; prevent progression to type 2 
diabetes in women with gestational diabetes and 
their offspring; prevent long-term cardiovascular 
disease in mothers with diabetes and their offspring 
and encourage an appreciation of the importance of 
sex- and gender-specific approaches to diabetes 
care (see also Milestones 2.2.01, 2.2.03, 3.2.03 
and Goal 3.4). 
 
Track 1. Mothers 
 
Milestone 4.7.01. Prevent gestational diabetes 
(GDM) and progression from GDM to type 2 
diabetes 
The genes, epigenetic mechanisms and the effect 
of environment (including lifestyle) in determining 
predisposition to impaired glucose 
tolerance/diabetes during pregnancy should be 
identified. Sub-groups of patients with 
predominantly beta cell dysfunction and those with 
predominantly insulin resistance should be 
distinguished and targeted therapy should be 
implemented in randomised controlled trials.  
 
Milestone 4.7.02. Develop new strategies to 
improve pre-pregnancy care in women with 
gestational diabetes and with pre-gestational 
diabetes  
Many women with hyperglycaemia are first 
detected early during pregnancy and are therefore 
at increased risk of diabetic embryopathy. Improved 
methods to detect prediabetes/unknown type 2 
diabetes prior to conception should be tested and 
validated also to target reduced fertility.  
 
Women with pre-gestational impaired glucose 
metabolism and diabetes should be identified and 
treated accordingly. Pre-pregnancy care 
programmes have to be optimised and validated for 
all women with pre-gestational diabetes. 
Investigation of educational programmes with better 
adherence and acceptance and new motivational 
strategies should be undertaken to develop 
programmes to improve preparation for pregnancy. 
In addition, special programmes should be 
developed and validated for ethnic minorities at 
particular risk for type 2 diabetes (see also Goal 
4.2). 
 
Milestone 4.7.03. Develop evidence-based 
standardised criteria for diagnosis and 
treatment goals of gestational diabetes 
The existence of different criteria for the diagnosis 
of GDM greatly limits comparison between regions 
and countries. The incidence of GDM in Europe is 
unclear as the diagnosis varies according to the 
test, diagnostic criteria, the ethnic group and the 
follow-up period. Therefore, it is essential that 
standardised criteria are developed and validated. 
This would allow clinical care delivery to be 
compared across Europe and ensure that Europe-
wide research studies can be compared and 
validated to improve treatment (see also Goal 4.1 
and Goal 4.2). 
 
The achievement of normoglycaemia during 
pregnancy is currently limited by increased risk of 
hypoglycaemia, in particular in the first half of 
pregnancy, and is the most common cause of 
maternal death. It is unclear if recurrent 
hypoglycaemia is harmful to the developing fetus. It 
is important to develop and validate new 
concepts/methods to achieve normoglycaemia, 
without hypoglycaemia before and during 
pregnancy.  
 
Currently the recommendations for weight gain 
during normal and diabetic pregnancy are 
inadequate. New studies are required to test and 
validate the optimal weight gain for pre-conception 
body mass index (BMI) categories (see also 
Milestone 4.4.02).  
 
Milestone 4.7.04. Test and validate treatment 
options  
Despite improvements in metabolic control, 
pregnancy outcomes for women with diabetes are 
still worse compared to those without diabetes. In 
addition to glucose control the impact of additional 
metabolic parameters such as lipids should be 
evaluated. Parameters of oxidative stress related to 
glucose peaks may play a role during pregnancy 
and use of antioxidants or vitamins could be useful 
in future therapy. 
 
Continuous glucose monitoring (CGM) should be 
explored and validated in diabetic pregnancies to 
improve the possibilities for metabolic control. 
These aspects of monitoring and treatment require 
prospective clinical trials. 
 
Milestone 4.7.05. Develop optimal strategies to 
prevent progression of complications in pre-
gestational diabetes  
Deterioration of diabetes complications, in particular 
retinopathy and nephropathy, is still a concern in 
diabetic pregnancies and is related to higher 
perinatal complication rates. Furthermore, pre-
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existing cardiovascular disease will increase due to 
the rapidly growing number of obese women with 
type 2 diabetes before pregnancy. 
 
Strategies should be developed and validated to 
identify risk factors and early biomarkers associated 
with progression of diabetes complications during 
pregnancy. With this knowledge, intervention 
programmes can be designed to prevent the 
progression of complications during and after 
pregnancy in women with pre-gestational diabetes. 
Educational programmes, prevention programmes 
and programmes for behaviour modification should 
be developed and validated to improve awareness 
in those individuals at risk. 
 
Track 2. Offspring  
 
Milestone 4.7.06. Understand fetal programming 
and gene/environment interaction 
Intrauterine milieu and fetal programming play 
important roles in the development of chronic 
diseases such as obesity, diabetes, vascular 
disease and hypertension in adult life. GDM, 
hypertension, overfeeding as well as famine are 
associated with increased long-term risks to the 
fetus. In addition, epigenetic mechanisms and 
gene/environment interactions affect the health of 
the offspring. Substrates and environmental factors 
may affect male and female offspring in different 
ways. These sex differences require further detailed 
investigation, as does the relationship between sex 
hormones, sex hormone-binding globulin and 
glucose/insulin metabolism and the risk of diabetes 
and diabetes complications in both sexes. 
 
Milestone 4.7.07. Understand diabetic 
embryopathy and fetopathy including sex-
specific differences 
Embryopathy (abortions, malformations) is the main 
cause of increased fetal and perinatal mortality and 
still a major concern in diabetic pregnancy. 
Fetopathy (macrosomia, fetal hyperinsulinism) is 
associated with life-long changes of 
neuroendocrine pathways related to obesity. The 
underlying mechanisms remain unclear. The 
pathophysiologic mechanisms and life-long 
sequelae of fetal growth abnormalities such as 
growth retardation and overgrowth require further 
study. Both are more common in diabetic 
pregnancies and are themselves linked to an 
increased risk of diabetes in the offspring.  
 
Milestone 4.7.08. Develop new targets and 
treatment concepts to avoid fetal 
hyperinsulinaemia and metabolic imprinting 
Understanding the causes of fetal 
hyperinsulinaemia would help to identify new 
therapies. No reliable treatment option is available 
at present to prevent fetal hyperinsulinaemia or 
metabolic imprinting. Therefore, new treatment 
options have to be tested first in animal models. 
The optimal therapy should then be tested and 
validated together with best surveillance of 
metabolic control in large randomised controlled 
trials with evaluation of both acute effects on fetal 
growth and perinatal outcome and long-term follow-
up of the offspring. New and more effective 
treatment options with no or minimal side effects, in 
particular without hypoglycaemia, and exclusion of 
potential harm to the fetus have to be developed, 
tested and validated.  
 
Track 3. Postpartum follow-up 
 
Milestone 4.7.09. Understand the long-term 
effects of breastfeeding on health of mother and 
child 
Breastfeeding is recommended for women with 
diabetes and thought to reduce the risk of obesity in 
their offspring. However, research in this area is 
limited and data controversial. This area requires 
much more detailed prospective study in relation to 
long-term effects on health and body weight of both 
the mother and child.  
 
Milestone 4.7.10. Avoiding weight retention in 
women after delivery 
Parity is an important contributor to overweight and 
obesity in women. This is likely to relate to 
hormonal changes, changes of adipokines and the 
increase in fat mass during pregnancy. Weight 
retention during the first year after delivery predicts 
further weight gain at follow-up. Weight reduction 
and behaviour modification programmes are 
needed and should be validated to prevent weight 
retention in particular after delivery in women with 
GDM and those with pre-gestational diabetes. 
Intervention should reduce progression to overt 
diabetes in women with prior GDM and prevent 
recurrence of GDM and its associated risks for the 
offspring in the subsequent pregnancy. 
 
Milestone 4.7.11. Prevent type 2 diabetes and 
cardiovascular disease following gestational 
diabetes  
Women with GDM have a seven-fold higher risk of 
frank diabetes compared to women with normal 
glucose tolerance. Biomarkers that identify those 
women at particular risk of gestational diabetes, 
diabetes and vascular disease have to be identified 
and validated.  
 
Although there are several diabetes prevention 
studies that included women with prior GDM, 
analysis of the results of this important sub-group at 
particular risk is missing in most studies or only 
performed retrospectively (post-hoc sub-group 
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analysis). Therefore, large prospective studies in 
well-characterised women with prior GDM with 
different phenotypes and genotypes have to be 
undertaken and intervention strategies designed 
and validated to prevent type 2 diabetes and 
cardiovascular disease after GDM as well as 
recurrence of GDM. 
  
Milestone 4.7.12. Prevent diabetes and obesity 
and cardiovascular disease in offspring  
Recent studies show an increased risk of obesity, 
prediabetes and even diabetes in the offspring of 
women with GDM and pre-gestational diabetes. In 
particular newborns with growth abnormalities 
(small for gestational age, large for gestational age) 
are at risk of development of the metabolic 
syndrome and an increase in cardiovascular risk 
factors early in life. Biomarkers that identify those 
children at particular risk of diabetes and vascular 
disease have to be identified and validated (see 
also Goal 6.2). 
 
Gender-sensitive risk scores for the offspring need 
to be defined. Large follow-up studies in offspring 
and prevention strategies will be necessary as part 
of the overall Goal to reduce and limit the epidemic 
of diabetes. 
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Goal 4.8. Relate islet function to clinical outcomes and clinical care 
 
 
   Roadblock 1. Ethical guidelines: in particular regarding data sharing and transfer, collection and use of biological  
    materials, including DNA  
   Roadblock 2. Variation, lack of standardisation or international consensus across Europe in laboratory conditions,  
    measurement techniques, sample handling  
   Roadblock 4. Lack of birth cohorts and registries with repeated examinations for long-term follow-up studies over 
    the life-course  
   Roadblock 12. Partnerships between academia and industry (both pharmaceutical and other industry) are needed 
 
 
 
Introduction and background 
Islet dysfunction is an early event in the cascade of 
metabolic defects leading to diabetes. Longitudinal 
studies have shown that insulin secretory defects 
and insulin sensitivity defects confer equal relative 
risks of developing diabetes in persons with 
apparently normal glucose tolerance. Temporal 
progression of the metabolic disorder is manifested 
by inadequate islet cell responsiveness to all 
secretagogues (a global defect) and to glucose in 
particular, by the time a susceptible individual has 
attained impaired glucose tolerance. Preventing 
islet deterioration is a major goal for the prevention 
of diabetes and for the prevention of progression of 
preexisting diabetes. Understanding the causes of 
islet impairment, developing simple methods to 
measure impaired islet function, and developing 
improved strategies for intervention are critical to 
helping the person with diabetes better manage 
their own condition and live a healthier life. This 
area of research is of great interest to the 
biotechnology and pharmaceutical industry as it 
directly applies to the development of therapies. 
 
The road maps for islet biology research (see also 
Goals 2.1-2.4) describe research directions 
focussed on the islet/beta cell itself (mostly in vitro 
studies to understand biochemical cascades, 
metabolic pathways, mitochondrial functions). In a 
complementary fashion, this clinical road map 
focusses on research with the ‘intact’ individual 
person in order to design more effective, simpler 
tests of islet function performed in the whole body 
and, ultimately, to develop interventions to restore 
islet function. Techniques of bioengineering and 
mathematical modelling are incorporated to better 
understand complex multi-organ pathophysiologic 
processes. An example would be the progression of 
beta cell failure as a function of changes in insulin 
sensitivity over the course of a diabetes prevention 
trial, or an intervention with incretin, or even in the 
years following stem cell transplantation (in the 
future). The aim is to yield an adequate restoration, 
and then maintenance, of the islet function, through 
pharmaceutical intervention, stem cells, 
transplantation, cell regeneration or growth, 
reduced apoptosis and other strategies.  
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Milestone 4.8.01. Identify people known to have 
islet dysfunction 
People with characteristics known to indicate islet 
dysfunction (e.g. diabetes itself, pancreatitis and 
other secondary forms of diabetes, but particularly 
the range of prediabetic conditions such as 
impaired fasting glucose, impaired glucose 
tolerance, former gestational diabetes) are needed 
to provide data to allow the development of 
methods to quantify specific indices that reflect islet 
function in vivo. Identification of such subjects can 
be made with simple typical criteria used routinely 
in clinical research, such as measurements of 
glucose, insulin, C-peptide, proinsulin, amylin at 
fasting and/or during oral or intravenous glucose 
tolerance testing (see also Milestone 4.8.04 and 
Goal 2.1). 
 
Milestone 4.8.02. Develop quantitative methods 
to measure various aspects of islet function in 
vivo in humans 
New, less demanding methods for characterising 
islet processes are needed in order to reduce the 
burden on patients and clinical researchers. Thus, 
simple, easy to perform tests with mathematical 
modelling in all its different forms, relatively non-
invasive, and able to be carried out at the subject’s 
bedside would facilitate research in large cohorts of 
subjects. Such methods would improve the 
precision and accuracy of the outcomes of large 
clinical research studies for diabetes. Other more 
sophisticated techniques, such as non-invasive 
imaging of the pancreas and islets, also need to be 
developed to provide further insight on specific 
parameters of islet function that cannot be 
measured directly including the poorly understood 
relative contribution of decreased beta cell mass 
and function to impaired islet function. 
 
Evaluation of islet function can be achieved by 
quantifying parameters related to insulin-mediated 
glucose control. The quantification can be attained 
through different approaches ranging from simple 
tests that, by perturbing the steady-state (usual) 
condition, clarify the different behaviour of the 
pancreas and peripheral insulin target tissues, to 
complex imaging analysis that provides information 
on a whole organ. For example, an intravenous 
injection of glucose that does not induce the 
‘proper’ insulin response is a marker of secretion 
impairment; similarly, the arginine infusion test can 
be used to evaluate the insulin reserve in the cell. 
Imaging is a fast-developing field with new 
techniques and approaches introduced 
continuously. Research to apply innovative 
methods, such as magnetic resonance imaging and 
positron emission tomography, to imaging of the 
pancreas should allow assessment of the 
concentration of molecules in vivo with high 
sensitivity. In addition, islets can be inspected in 
order to evaluate their mass, vascularity, apoptosis, 
infiltration and other parameters that might be 
important in diabetes patients. 
 
Eventually, the development of more ‘user friendly’ 
tests of islet function could provide detailed, useful 
information on a person’s health status and may be 
used by general practitioners (family doctors) or by 
people with diabetes to stage and manage their 
own condition (see also Milestones 4.08.04, 
4.8.05). 
 
Milestone 4.8.03. Relate quantitative 
measurements of islet dysfunction to other 
variables/processes in humans. The aim here will 
be to quantify the role of islet impairment in the 
general diabetes picture and determine islet factors 
needing intervention. Diabetes is a multifaceted 
disease, but the role of islet dysfunction is 
fundamental. Quantifying islet dysfunction in 
diabetes would allow researchers to better 
characterise the processes through which islet 
dysfunction leads to eventual islet failure. Since 
islet function is related to processes occurring 
outside of the pancreas, other variables and 
physiologic mechanisms must be quantified to find 
possible relationships between measurements of 
islet dysfunction and measurements of these other 
variables (e.g. insulin resistance, glucagon, lipids, 
HbA1c, incretins, liver function, renal function). For 
instance, understanding the relationship between 
insulin sensitivity in liver, skeletal muscle and 
adipose tissue, and beta cell sensitivity to glucose 
could clarify the role of insulin release in insulin-
resistant states. Physicians could therefore 
intervene in a more focussed way, knowing whether 
the main defect in an individual patient is at the 
level of insulin action or insulin secretion. In the first 
case, just restoring islet function may not be 
enough to effectively treat a person with diabetes. 
 
Milestone 4.8.04. Determine islet factors 
needing intervention 
Once it has been assessed that islet function is 
compromised according to specific criteria arising 
from the observation of known dysfunctions (see 
Milestone 4.8.01), assessing the relative 
contribution of the various components of the islet 
dysfunction (see also Chapter 2) would allow for 
more sharply targeted and hopefully more effective 
intervention.  
 
Milestone 4.8.05. Evaluate methods (existing 
and new) to restore adequate islet function  
Data from previously conducted clinical trials in 
selected groups of subjects should be (re-) 
evaluated to assess the outcomes of the 
interventions. At the same time, new trials must be 
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designed and promoted to validate new methods 
(see also Milestone 4.8.02) aimed to restore 
adequate islet function. Methods to be explored 
would be genetic manipulation, stem cells, 
pharmaceutical interventions, monitoring and 
artificial delivery systems. In the case of 
pharmaceutical interventions, a major emphasis 
must be placed on distinguishing between true 
(sustained) restoration of islet function and the 
acute effects of the drug.  
 
This Milestone will require the design, development 
and implementation of specific software 
(bioinformatics) for (user friendly) data analysis with 
mathematical modelling, microarrays, and other 
advanced techniques. Simulation/modelling may 
also be used, but only after a thorough validation 
against real data both arising from the prior 
experiments and from new specifically designed 
tests. 
 
Milestone 4.8.06. Evaluate the necessary 
conditions for performing and monitoring islet 
transplantation  
For any type of surgery it is necessary to evaluate 
whether the intervention is feasible (the condition of 
the patient), but also all the steps mentioned above 
are essential in monitoring the progress of islet cell 
transplantation, because they help to indicate the 
success (or not) of the intervention itself. 
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Goal 4.9. Prevent and/or reduce cognitive impairment and psychopathology in 
diabetes 
 
 
   Roadblock 3. Practical and ethical challenges of locating research participants among diverse groups 
   Roadblock 16. Barriers in the multidisciplinary approach to guiding people with diabetes through health care    
   structures (e.g. referral from primary to hospital care and back)  
 
 
 
Introduction and background 
Cognitive impairment and psychopathologies 
including depression, anxiety and eating disorders, 
occur more frequently in people with diabetes 
relative to those without the disease. Cognitive 
impairment and psychopathology reduce quality of 
life and affect long-term outcomes. Barriers to 
research in this field have included uncertainty 
regarding the causal relationships between 
diabetes and cognitive impairment/ 
psychopathology; lack of knowledge regarding the 
diabetes-specific effects on these conditions; lack 
of information about prevalence; methodological 
issues in diagnosis, measurement and 
classification.  
 
Cognitive impairment and psychopathology can 
worsen glycaemic control and outcomes, thus it is 
important that novel research approaches are 
addressed to the above areas of uncertainty. The 
overarching Goal of this road map therefore is to 
prevent and/or reduce cognitive impairment and 
psychopathology in diabetes, by stimulating 
research activities that will study specific 
(molecular) mechanisms that lead to the 
development of cognitive impairment and 
psychopathology, specifically in people with 
diabetes. Be able to identify people at the highest 
risk of developing these conditions and develop 
and validate interventions for prevention and cure 
of these conditions. (See also Milestones 1.4.07, 
3.1.12, 4.5.02 and Goals 3.4, 4.3, 4.5). 
 
Milestone 4.9.01. Understand development of 
changes in brain structure and function in 
general  
Normal ageing is associated with changes in brain 
structure and function. Changes in the brain may be 
different in men and women, as sex hormones 
influence brain function and behaviour. Prospective 
studies are required to investigate these processes 
in patients with diabetes. Such research would 
include serial measurements of parameters of brain 
function and structure, and the correlation between 
these changes and the sequential evolution of 
diabetes itself and its complications (see also 
Milestone 3.1.12).  
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Milestone 4.9.02. Understand quantitative and 
qualitative aspects of cognitive impairment in 
diabetes 
Prospective animal and human studies are required 
to investigate the effects of diabetes on cognitive 
function. This line of research would include 
autopsy studies in patients where appropriate pre-
mortem clinical histories are available. 
 
Milestone 4.9.03. Understand quantitative and 
qualitative aspects of diabetes-specific 
psychopathology  
Diabetes itself may be a risk factor for the 
development of cognitive impairment and 
psychopathology, and the occurrence of some of 
these conditions has been ascribed to the risk of 
complications. Research is required to understand 
the cause-consequence relationship between these 
common chronic diseases. Large cohort studies are 
clearly required to achieve the necessary statistical 
power. Early (prevention, pathophysiology) as well 
as long-term (to understand the progression and 
development of the disease entities) monitoring and 
the use of various methods [validated 
questionnaires and tests; non-invasive imaging 
(see also Milestone 3.1.12)] will be required. 
 
Milestone 4.9.04. Understand diabetes-specific 
mechanisms causing changes in brain structure 
and function 
Recent data indicate that diabetes adversely affects 
brain structure and function by directly affecting 
neurons and associated cells or via its effects on 
the vasculature. It will be important to distinguish 
between direct metabolic effects and those possibly 
driven by altered insulin action in the brain in 
diabetes. However, in humans these data are 
unavailable because of limited access to brain 
tissue for the necessary investigations. Progress 
will not be made in this area until it becomes 
possible to study human brain tissue more directly 
either in vivo (with novel less invasive probes) or 
post-mortem, with the appropriate consent and 
clinical history and collateral information. 
 
Milestone 4.9.05. Identify markers and 
predictors of cognitive impairment and 
psychopathology in diabetic patients and 
specific subpopulations  
In order to map the progress to cognitive changes 
and psychological diseases in patients with 
diabetes, prospective studies are required with a 
multidisciplinary approach incorporating basic 
research and clinical science. The aim of this 
research strategy is to describe markers of risk and 
progression to cognitive impairment and 
psychopathology in patients who are healthy at 
baseline. 
 
Milestone 4.9.06. Develop predictive tools for 
risk of cognitive and psychological disease 
Simple tests that reliably predict future cognitive 
impairment and psychopathology in people with 
diabetes and specifically allow early detection of 
high-risk groups are an important research Goal. 
These types of prospective studies are required in 
diabetes patients in general, but there are specific 
vulnerable sub-groups in whom such research 
could be prioritised, including children who develop 
diabetes at a very young age, adolescents, and 
adult patients with diabetes-related complications 
[to investigate the primary development of the 
central nervous system (CNS) complications]. 
Equally important are those patients with pre-
existing cognitive impairment and psychopathology, 
who have then developed diabetes (i.e. to 
investigate the effect of diabetes on the rate of 
secondary progression of the already existing CNS 
diseases).  
 
Milestone 4.9.07. Develop and implement 
strategies to prevent or treat target populations 
Treatments for cognitive decline and 
psychopathology in individuals with diabetes should 
be compared and evaluated in randomised 
prospective clinical trials.  
 
Milestone 4.9.08. Evaluate cost-effectiveness, 
monitor trends in risk factor control and quality 
of preventive healthcare services  
The costs of long-term care of those with cognitive 
impairment or serious psychological illness are 
enormous. Evaluation of the cost-effectiveness of 
the development and application of all interventions 
in patients with diabetes, both preventive and 
therapeutic, is therefore a high priority. Thus, 
specific allocation of budgets or shifting them to 
prevent and treat cognitive impairment/ 
psychopathology in diabetes will require an 
evidence base.  
 
Milestone 4.9.09. Evaluate efficacy in relation to 
patient outcome and health economics  
In addition to the above research strategies, an 
ultimate one is the measurement and evaluation of 
these interventions on patient outcome and on 
overall health economics. 
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Goal 4.10. Develop new strategies to minimise the risk of hypoglycaemia (including 
technologies) 
 
 
 
   Roadblock 1. Ethical guidelines: in particular regarding data sharing and transfer, collection and use of biological  
    materials, including DNA  
   Roadblock 7. Lack of specific bioinformatic software to analyse and integrate multiple data 
   Roadblock 10. Resistance to implementation of large-scale clinical research in the setting of usual clinical care 
   Roadblock 12. Partnerships between academia and industry (both pharmaceutical and other industry) 
   Roadblock 13. Huge differences in structure, process, quality and delivery of diabetes care between European  
    countries  
   Roadblock 14. Advances in diabetes treatment or new drugs or new devices can only be implemented if society is  
   able to support such treatments  
 
 
 
Introduction and background 
Despite advances in the technology of insulin 
delivery, self-monitoring of interstitial and blood 
glucose and structured patient education, 
hypoglycaemia (low blood glucose) remains an 
important consideration for people with diabetes 
and healthcare professionals. The consequences of 
even a single episode of hypoglycaemia can range 
from a minor nuisance to major disruption in daily 
life for people living with diabetes. Consequently, 
some individuals resist attempts by the diabetes 
team to intensify insulin therapy leading to poor  
control and diabetes complications. Regular 
episodes of hypoglycaemia can limit employment, 
driving and educational attainment, and shorten life. 
There is also decreased awareness of 
hypoglycaemia with increasing number of episodes. 
The socioeconomic costs of dealing with severe 
hypoglycaemia are considerable. The Goal is 
therefore to minimise the risk of hypoglycaemia in 
people with diabetes. This will be reached by three 
convergent research tracks. 
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Track 1. Healthcare systems (to provide 
universal access to quality assured structured 
education, modern insulin-delivery systems and 
glucose monitoring technologies according to 
clinical need) 
 
Research suggests that severe hypoglycaemia can 
be reduced by participation in structured education 
and by technology, including continuous 
subcutaneous insulin infusion (CSII-insulin pump 
therapy), continuous interstitial glucose monitoring 
(CGM) as well as traditional finger-stick blood 
glucose monitoring. Access to technology is limited 
with significant geographic variation across Europe. 
Even when patients can access technology, 
hypoglycaemia and the threat of very low glucose 
levels remains a major limitation in day-to-day life 
with diabetes.  
 
Milestone 4.10.01. Understand the factors 
limiting access to and uptake of education 
programmes 
Both for type 2 as well as type 1 diabetes, specific 
qualitative research is needed to investigate the 
barriers to comprehensive education in self-
management. Telehealth is already used in some 
locations as a means to provide education, and to 
monitor from the home and provide intervention and 
feedback as necessary. This could be extended to 
investigate barriers to update of education and to 
develop new educational services. 
 
Milestone 4.10.02. Develop optimum health-
economic strategy to incorporate currently 
available systems for monitoring blood glucose 
in type 1 and type 2 diabetes 
Optimisation of blood glucose monitoring systems 
including better understanding of factors influencing 
performance such as accuracy (e.g. drug 
interactions) and comparisons between systems 
are required particularly for the early detection of 
hypoglycaemic events. More research needs to be 
done to develop the most cost-effective approach to 
glucose monitoring for different classes of therapies 
tailored to individuals. 
 
Milestone 4.10.03. Understand the most cost-
effective approach to deliver insulin for people 
with type 1 and type 2 diabetes  
This will require study of the use of insulin-delivery 
systems, including collaboration with industry to 
reduce the cost and improve the convenience of 
these devices. Such studies require research into 
training and education as well as psychosocial 
influences, and numeracy and literacy.  
 
Track 2. Reverse abnormal glucose counter-
regulation 
 
The brain depends on a continuous supply of 
glucose from the peripheral circulation. Patients 
treated with insulin and oral sulphonylureas are at 
risk of hypoglycaemia. As blood glucose starts to 
fall, this is ‘sensed’ predominantly by the 
hypothalamus area of the brain, which switches on 
a complex hierarchy of physiological responses 
consequent upon activation of the autonomic 
nervous system. These include development of 
early warning symptoms to alert the individual to 
take appropriate action such as ingesting 
carbohydrate. Release of hormones (glucagon, 
adrenaline, noradrenaline, cortisol and growth 
hormone) all have the opposite effect to insulin i.e. 
they increase glucose production by the liver and 
reduce glucose use by muscle.  
 
In order to reverse abnormalities in the central 
nervous system (CNS) response to hypoglycaemia, 
both clinical and basic investigations are required. 
At the level of clinical research these will include 
non-invasive and invasive approaches with the 
measurement of biochemical and other markers 
along with imaging, including functional magnetic 
resonance imaging and other novel imaging 
technologies. 
 
Milestone 4.10.04. Understand the genesis of 
hypoglycaemia unawareness 
A proportion of patients lose hypoglycaemia 
awareness, usually after longstanding diabetes. 
The research strategy would include the 
recruitment of cohorts of patients who do and do 
not have these features and dissecting the causes 
of differences in hypoglycaemia awareness in 
otherwise comparable subjects. This research 
would include the development of predictive 
markers and models for this serious complication 
(see also Milestone 3.1.12). 
 
Milestone 4.10.05. Prevent loss of early warning 
symptoms to detect the onset of hypoglycaemia 
and recovery of these symptoms in 
hypoglycaemia unaware individuals 
Hypoglycaemia unawareness can be transient, 
such as during pregnancy, or more permanent after 
many years of diabetes and is invariably associated 
with defective glucose counter-regulation. It is also 
associated with recurrent episodes of low blood 
glucose, i.e. hypoglycaemia begets hypoglycaemia. 
Three clinical categories are recognised: a 
complete failure to develop early warning 
symptoms; generation of early warning symptoms 
but failure to relate them to a low blood glucose 
because of cognitive impairment (due to 
neuroglycopoenia); generation of early warning 
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symptoms with an understanding that they are 
caused by low blood glucose but an inability to take 
appropriate action. Research should address 
patient cohorts in each of the above distinct 
categories. Studies would include the testing of 
novel strategies for prevention as well as reversal 
of hypoglycaemia unawareness. Different 
approaches are required in sub-groups of patients 
including children, adults and the elderly. 
 
Milestone 4.10.06. Develop interventions to 
reverse abnormal glucose counter-regulation  
Complex physiological mechanisms defend against 
severe hypoglycaemia. These include activation of 
the autonomic nervous system and release of 
counter-regulatory hormones. For people with type 
1 diabetes, release of glucagon in response to 
falling glucose is lost after 5 years of diabetes. After 
10 years many patients also have attenuated 
adrenaline responses, increasing the risk of severe 
hypoglycaemic events. Prospective human studies 
are required to understand the temporal sequence 
of these alterations in defensive physiology in 
patients with various forms of diabetes. Further to 
this, specific interventional approaches require 
formal study and comparison in these cohorts to 
test and validate novel treatment approaches such 
as the meticulous avoidance of hypoglycaemic 
episodes, nutritional interventions and technological 
devices.  
 
Track 3. Individualising treatment 
 
Milestone 4.10.07. Develop a non-invasive 
device for detecting the onset of hypoglycaemia 
linked to an insulin-delivery system 
A highly desirable component of diabetes 
management is a non-invasive glucose monitoring 
system. Any closed-loop insulin-delivery system 
requires accurate glucose measurement (sensing) 
coupled with a reliable algorithm for determining 
insulin dose, timing and delivery with minimal 
user/patient input. The connection of CGM with 
CSII by a mathematical algorithm to form an 
‘artificial pancreas’ is a major milestone along this 
research track.  
 
Novel research approaches to closed-loop systems 
for insulin delivery are a high priority. Specific 
approaches will require collaboration between 
clinicians, engineers, mathematical modellers, and 
industry in order to design studies and specific 
intervention programmes to test novel device 
systems and combinations in various cohorts of 
patients at different stages of diabetes. 
 
Milestone 4.10.08. Determine the most cost-
effective method of acting upon the information 
provided by closed-loop systems 
Further to the research outlined above, a broad 
qualitative and quantitative research approach is 
required to study the: 
• cost of the closed-loop system 
• size: anecdotally the most common reason for 
declining a technological approach remains a 
reluctance to be ‘attached to a machine’ 
• requirement for finger-stick glucose monitoring 
for calibration  
• acceptability and effectiveness of 
intermittent/episodic use of the system 
• confounding effect of concomitant medications 
and electronic devices and physical conditions 
(altitude, temperature etc) 
• role of literacy and numeracy of the user. 
 
Milestone 4.10.09. Test appropriateness of 
individualising the use of the data generated 
Individualisation of treatment includes consideration 
of age group, stage of disease, travel, shift work 
and inter-current illness. Technology developments 
can assist this process of individual customisation: 
these include bolus calculators, multiple bolus 
options and alterations in basal infusion rates in 
insulin pumps. Furthermore, new systems are likely 
to have the facility for add-on applications to aid in 
diabetes management beyond simply the recording 
of a single blood glucose value. These will include 
data management systems, personalised diet 
histories to examine the previous glycaemic 
fluctuations with certain meals and the impact of 
exercise, alcohol and travel, and perhaps for weight 
management. The next generation are also likely to 
incorporate telehealth functions and be smaller 
infusion devices, perhaps with the hand-held 
component having the facilities for social 
networking and sending SMS messages.  
 
Significant barriers will need to be overcome but 
they are not in the true sense immovable 
roadblocks to research in that they could be 
resolved with appropriate collaboration and funding. 
These include the lack of a rapid-acting insulin with 
consistent and reproducible insulin absorption and 
action Currently available real-time monitoring 
systems are not non-invasive and require 
calibration. The physiological lag between 
interstitial and blood glucose measurements would 
need to be overcome. There is no fail-safe 
algorithm for relating insulin delivery to glucose 
measurements. There is interference with some 
glucose measurement techniques by other 
medications such as maltose and paracetamol. The 
cost of the system. 
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Goal 4.11. Improve prognosis and quality of life by developing strategies to achieve 
clinical targets in different dysglycaemic populations 
 
 
   Roadblock 1. Ethical guidelines: in particular regarding data sharing and transfer, collection and use of biological  
    Materials including DNA  
   Roadblock 2. Variation, lack of standardisation or international consensus across Europe in laboratory conditions,  
    measurement techniques, sample handling and clinical diagnoses and practice  
 
 
Introduction and background 
There is increasing recognition that general 
guidelines and treatment algorithms for diabetes 
are difficult to fit into clinical practice. Furthermore, 
treatment algorithms have come under criticism 
recently for their lack of foundation on an evidence 
base.  Particularly for type 2 diabetes, the 
heterogeneity between patients is so wide that it is 
difficult and unscientific to generalise treatment 
recommendations.  The long natural history of type 
2 diabetes and its gradual progression run in 
parallel with the life-course of the patient, and with 
other co-morbidities.  All of these components of 
temporal evolution of diabetes in the setting of the 
life of the individual call for a greater focus on 
personalised treatment – and a lesser reliance on 
general guidelines that may not ‘fit’ the needs of the 
individual. 
 
Recent evidence shows that certain groups of 
patients may face increased risks (for example, for 
cardiovascular events) at HbA1c below 7.5 percent. 
Thus there is a need for better staging of patients 
according to diabetes phenotype, duration of 
disease, stage of life and the presence or absence 
of complications. Glucose targets (and other 
treatment targets) probably need to be different for 
these different sub-groups. Thus, early diagnosis 
and early treatment to near-normal glucose target 
in newly diagnosed patients (prior to the onset of 
complications) is likely to yield excellent long-term 
outcomes, as has been shown by analysis of the 
United Kingdom Prospective Diabetes Study 
(UKPDS). However, aggressive treatment to target 
in older patients with longer-duration disease (and 
cardiovascular complications, whether diagnosed or 
silent) may increase cardiovascular risk and risk of 
mortality. Studies in new large population cohorts 
will be necessary to support this research strategy, 
and prospective studies are now needed to address 
these questions. 
 
The overall Goal of this map is to improve 
prognosis and quality of life in specific target 
populations of patients with diabetes (see also 
Milestones 1.4.08, 1.4.09, 1.5.09). 
 
Milestone 4.11.01. Generate disease cohorts 
Large collaborative networks will be required to 
generate study populations sufficiently powered to 
address these complex questions. One way to 
achieve this in Europe is the European Platform for 
Clinical Research in Diabetes (EPCRD). The first 
step is therefore to create large registries of 
diabetes patients, who will have consented to be 
studied in this way, classified initially according to 
age (life-phase), sex, date of diagnosis of diabetes 
and disease phase (see also Goal 4.1).  This 
approach could then incorporate many cohorts with 
different characteristics, particularly age, but also 
gender, duration of diabetes, urban or rural setting, 
region within Europe etc. 
 
Milestone 4.11.02. Identify biomarkers relevant 
to disease progression 
When the large disease cohorts have been 
identified from Milestone 4.11.01 the next stage will 
be to undertake large-scale phenotyping in order to 
study a wide range of biomarkers relevant to 
disease progression and the risk of complications, 
including a search for novel markers and predictors 
of later outcomes. These would include: C-peptide, 
immune and inflammatory markers, HbA1c, lipid 
profiles, genetic markers, other novel markers (see 
also Milestone 1.5.09). A large-scale international 
diabetes clinical biobanking project is envisaged 
here. This approach would be greatly strengthened 
if established in the framework of the EPCRD, as 
has been outlined previously (Goal 4.1). Such an 
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integrated framework would allow the study of 
phases of disease progression and the onset of 
relevant complications and clinical endpoints (in 
specifically defined sub-populations) on a scale 
never previously possible.   
 
Milestone 4.11.03. Investigate overall study 
outcomes compared with metabolic treatment 
goals 
The questions raised by recent outcome studies 
require further investigation in large-scale 
prospective randomised controlled clinical trials. 
Thus, the central question of overall outcome 
compared with metabolic treatment goal (HbA1c) in 
early- compared with late-phase patients requires 
prospective study. A Europe-wide trial network 
could deliver such studies, which require very large 
scale and power to address and answer these 
complex questions.  Many clinical outcomes could 
be similarly studied by this approach. 
 
Milestone 4.11.04. Develop individualised 
diabetes health service provision plans based 
on disease stage and stage of life  
The approach outlined in this map can form the 
basis for health service planning for diabetes, 
taking a more streamlined approach to care based 
on the stage of disease and stage of life of the 
individual patient (see also Goal 4.5). 
 
Large-scale prospective randomised trials as 
described above allow the estimation and 
comparison of costs of care along different ‘tracks’, 
for example the cost of prevention of complications 
compared with the costs of more intensive 
treatments, regional comparisons, comparisons by 
age group to evaluate cost-effectiveness. The true 
costs of diabetes-related late complications have 
already been quantified in various studies in 
Europe, and amount in total to up to 10 percent of 
national health budgets. What has not been studied 
sufficiently are the costs of preventive care, and in 
particular those at specific stages of life and stages 
of disease evolution.  This type of analysis will be 
facilitated by the EPCRD, (see also Goal 4.1). The 
overall goal of this research approach is to be in a 
position to target investment and clinical resources 
in the best way to improve the overall prognosis of 
people with diabetes, and to improve their quality of 
life, regardless of where they live, their age and 
their stage of disease evolution. 
 
 
 
 
 
 
 
 
 
 
  
 
  112 
Roadblocks Chapter 4 
 
Roadblock 1. Ethical guidelines: in particular 
regarding data sharing and transfer, collection and 
use of biological materials including DNA 
Guidelines on data privacy are extremely complex and 
many are highly restrictive. Individual countries are likely 
to have different approaches to data handling and patient 
confidentiality.  
 
Roadblock 2. Variation, lack of standardisation or 
international consensus across Europe in laboratory 
conditions, measurement techniques, sample 
handling and clinical diagnoses and practice 
Lack of standardisation in laboratory assays (such as 
HbA1c, insulin and lipids) and in clinical practice means 
the same clinical picture can be managed differently in 
both quantitative (because of laboratory variability) and 
qualitative terms thus impacting on validation of clinical 
research in different settings. In diabetic pregnancy there 
is also no international consensus for the diagnosis of 
gestational diabetes mellitus or a standardised oral 
glucose tolerance test for such cases.  
 
Roadblock 3. Practical and ethical challenges of 
locating research participants among diverse groups 
Locating research participants is challenging among 
socially diverse groups (including: ethnicity, older age or 
early ageing, low socio-economic status, 
psychopathology and cognitive dysfunction, overweight 
and obesity). Barriers exist at several levels: limited 
literacy means potential participants are unaware of 
projects or of the research implications of those studies. 
Individuals in such groups often have sub-optimal health 
care service delivery. Unintentional labelling and 
stigmatisation caused by participation could impose 
negative attitudes towards changing behaviour. New 
strategies should be developed in order to increase 
participation, especially if barriers exist related to social 
background,  
 
Roadblock 4. Lack of birth cohorts and registries 
with repeated examinations for long-term follow-up 
studies over the life-course  
For research in pregnancy, childhood, normal ageing and 
ageing in diabetes there is a lack of diabetes registries 
(national and international).  With diabetes of long 
duration (50-60 years) this also means that people 
already diagnosed with diabetes can ‘lose’ this diagnosis 
when admitted to hospital or long-term care, resulting in 
confusion and inappropriate treatment. Research on cost 
-effectiveness and its application to health care policy 
require such long-term data. For example morbidity from 
gestational diabetes mellitus is often mild and treatment 
expensive. The long-term benefits to mother and child 
are difficult to calculate and need follow-up of up to 20 
years.  
 
Roadblock 5. Lack of large European diabetes 
networks  
There is a lack of networks focussing on clinical aspects 
of diabetes treatment those that do exist are mainly 
supported by pharmaceutical companies. This means 
there is a lack of reference centres, and experts in 
specialities such as paediatrics. 
 
Roadblock 6. Fragmented electronic medical records, 
even within a single institution 
Alongside the fragmented electronic records system is 
the lack of integration of the laboratory record (which may 
prove the presence of undiagnosed diabetes) with the 
main clinical record. 
 
Roadblock 7. Lack of specific bioinformatic software 
to analyse and integrate multiple data. This applies to 
data on biological (genetic), psychological, lifestyle and 
social factors. New bioinformatic approaches (e.g. 
Google Health) have the potential to revolutionise the 
way that medical data are stored and transferred; 
however, they are not available to benefit specific sub-
groups (e.g. children) with a chronic disease such as 
diabetes.  
 
Roadblock 8. Gap in professional skills 
The different skills between generalists, who provide 
most of the care to patients with diabetes in hospitals and 
institutional settings, and diabetes specialists, who work 
mostly in ambulatory care is a research roadblock.  
 
Roadblock 9. Lack of appropriate specific 
professional training and education 
This lack pertains to physicians and health care 
professionals providing treatment and care in specialised 
treatment centres, and referring patients from general 
health care settings.  
 
Roadblock 10. Resistance to implementation of large-
scale clinical research in the setting of usual clinical 
care and fragmentation of usual clinical care from the 
tradition of clinical research 
This includes difficulties with ethics approval, intellectual 
property, language, culture and simple logistics. These 
barriers result in fragmentation of usual clinical care from 
the tradition of clinical research with a lack of awareness 
of research issues. 
 
Roadblock 11. Drug regulatory issues: paediatric 
drug approvals lag behind adult decision-making in 
the regulatory pathway  
The EMA needs to have sufficient paediatric scientific 
input to put promising drugs and technological advances 
on an accelerated pathway without compromising safety 
to make them available also for the young age group and 
pregnant women at the earliest possible stage.  
 
Roadblock 12. Partnerships between academia and 
industry (both pharmaceutical and other industry) are 
needed 
Such partnerships (that might also include SMEs) are 
necessary for the development and bringing to market of 
new drugs and devices, especially in the area of 
paediatrics where they are still limited. Additional 
incentives and support are needed.  
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Roadblock 13. Huge differences in structure, 
process, quality and delivery of diabetes care 
between European countries  
Such differences are especially apparent in specialties 
such as paediatrics and obstetrics and in particular sub-
groups. They must be taken into account when 
researching and testing interventions in the clinical 
setting.  
 
Roadblock 14. Advances in diabetes treatment or 
new drugs or new devices can only be implemented 
if society is able to support such treatments 
In particular, discrimination against children with diabetes 
and lack of support in school and the peer-group 
environment make it very difficult for families to 
implement advanced therapy. Also, national differences 
can lead to inequality of access to new therapy across 
Europe.  
 
Roadblock 15. Lack of appropriate animal models to 
study fetal programming, fetopathy and embryopathy 
There are ethical issues in studying these processes in 
pregnant women because of the risk of harm to the 
developing fetus, and thus only observational studies can 
be undertaken. 
 
Roadblock 16. Barriers in the multidisciplinary 
approach to guiding people with diabetes through 
health care structures (e.g. referral from primary to 
hospital care and back) 
Collaboration is required for joint studies of diabetes and 
cognitive/psychological diseases and is particularly 
challenging for inter-disciplinary research that will require 
major commitment of resources and joint structures.  
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